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Abstract
To facilitate fine-scale phenotyping of whole specimens, we describe here a set of tissue fixation-
embedding, detergent-clearing and staining protocols that can be used to transform excised organs 
and whole organisms into optically transparent samples within 1–2 weeks without compromising 
their cellular architecture or endogenous fluorescence. PACT (passive CLARITY technique) and 
PARS (perfusion-assisted agent release in situ) use tissue-hydrogel hybrids to stabilize tissue 
biomolecules during selective lipid extraction, resulting in enhanced clearing efficiency and 
sample integrity. Furthermore, the macromolecule permeability of PACT- and PARS-processed 
tissue hybrids supports the diffusion of immunolabels throughout intact tissue, whereas RIMS 
(refractive index matching solution) grants high-resolution imaging at depth by further reducing 
light scattering in cleared and uncleared samples alike. These methods are adaptable to difficult-
to-image tissues, such as bone (PACT-deCAL), and to magnified single-cell visualization 
(ePACT). Together, these protocols and solutions enable phenotyping of subcellular components 
and tracing cellular connectivity in intact biological networks.
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 INTRODUCTION
Because of their intrinsic transparency, the worm Caenorhabditis elegans and the zebrafish 
Danio rerio provide scientists with an unobstructed, organism-wide view of tissue anatomy 
and cellular activity via, e.g., cell type–specific fluorescence labeling and genetically 
encoded calcium indicators1–3 and conventional imaging techniques4–6. In combination with 
their small size and genetic tractability, their whole-body transparency enables rigorous, 
high-throughput investigations into how environmental, cellular and genetic alterations 
influence biological processes from cellular signaling and apoptosis, to organism 
development and survival. By contrast, the comparatively large size and optical opacity of 
mammalian models generally has limited researchers to imaging snapshots of cellular 
organization on thin-sectioned tissue samples. However, it was hypothesized that if the 
bodies of these mammalian model organisms were to acquire the same level of optical 
transparency as zebrafish embryos, whole-body image data sets would theoretically become 
available to scientists for study (Table 1).
Several methodologies for tissue clearing have been proposed for large-scale 3D mapping of 
tissue macromolecular content7–21. Each of these protocols offers distinct advantages, such 
as preserving tissue architecture7,14,18,22,23, accommodating standard histological 
techniques8,15,17,18,24,25 or creating a computational workflow for acquiring and/or 
reconstructing thick-tissue image stacks11,15,14,26. Building on our prior CLARITY 
technique and concepts for generating extractable tissue-hydrogel hybrids8,27, we further 
developed the trio of PACT, PARS and RIMS to offer a user-friendly, rapid approach to 
rendering whole organs and whole organisms transparent18. These methods help to stabilize 
tissue architecture and preserve the macromolecular content of samples, thus enabling 
imaging of immunohistochemical, single-molecule RNA fluorescence in situ hybridization 
(smFISH), and small-molecule staining throughout thick tissues, as well as enabling long-
term storage18. In this protocol, we provide detailed information about how to implement 
PACT, PARS and RIMS so that users can apply these methods to their own research.
Imaging of large volumes of cleared tissue can generate gigabyteto terabyte-sized data sets, 
which creates new challenges associated with the computational analysis of the high-
resolution image stacks. Tract-tracing in particular is a difficult and laborious undertaking, 
whether for mapping the brain connectome or for generating a smaller-scale wiring diagram 
of isolated projections between specific brain regions or of peripheral nerves at target 
organs. Thus, in conjunction with refining methodologies to render tissues transparent, we 
evaluated a wide range of image analysis software packages for their ability to process data 
sets of cleared brain volumes. On the basis of our findings regarding the best-performing 
tools, we propose here sample workflows to provide users with a springboard for basic 
image analysis to complement and facilitate their adoption of the PACT, PARS and RIMS 
methods.
 Advantages of tissue clearing by tissue-hydrogel hybrids
The tissue stabilization and clearing methods that we developed8,18,27 use gentle delivery of 
structural supportive hydrogels and removal of light-obstructing lipids through either passive 
clearing (PACT) or through the vasculature of intact postmortem organisms (PARS). The 
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hydrogel mesh itself is transparent, and it secures proteins and nucleic acids into place so 
that we can later detect them with fluorescent labels under a microscope. There are a number 
of tissue clearing protocols available that combine the use of `chemical' clearing methods 
(i.e., the modification and/or removal of tissue components) and `optical' clearing methods 
(i.e., the homogenization of refractive indices (RIs) throughout the sample and sample 
mount, a feat that is usually accomplished through sample hyperhydration, dehydration 
and/or immersion in specially designed mounting solutions) in order to maximize sample 
transparency28. We experimented with many of these protocols alongside our initial 
development18 of PACT and PARS so that we could endeavor to incorporate some of their 
strengths and avoid major pitfalls. For example, we recognized the hydrogel-based tissue 
stabilization of CLARITY8,24 to be beneficial to sample integrity, the rapidity of 3DISCO14 
and the decolorization of CUBIC11,21 to be highly desirable, and the risk of tissue damage 
via burning8,24 or unchecked swelling9 to be best avoided. Our observations are summarized 
in Table 2 to guide researchers in selecting a clearing protocol that best suits their clearing 
application.
Emerging from these different approaches to tissue clearing, PACT and PARS are notable 
for their versatility in preparing a variety of tissue types for high-resolution imaging at 
depth. The PACT hydrogel formulation and clearing process is easily optimized to render 
difficult-to-image tissues transparent (e.g., PACT-deCAL, for PACT delipidation and 
decalcification of bone), to expand tissues for better separation of compact structures (e.g., 
ePACT, for PACT-based expansion clearing of dense cells or projections) and to preserve 
tissue integrity in fragile samples through varying the degree of paraformaldehyde-tissue 
cross-linking. Meanwhile, PARS is positioned to tackle a variety of scientific problems that 
would benefit from a comprehensive, whole-body view of gene expression patterns, cellular 
organization and/or structural composition.
PACT- or PARS-based preparation and clearing of tissue, followed by tissue mounting in 
RIMS, can preserve the signal from native fluorescent proteins and improve the efficacy of 
postclearing immunofluorescence labeling (Fig. 1). Fluorescence signal intensity is also 
maintained through month-long storage periods post fixation18. Other brain-specific tissue 
clearing protocols (Table 2) have at least one functional drawback, such as incompatibility 
with endogenous fluorescent labels. Some of these limitations have been overcome by the 
use of automated tissue sectioning techniques29–32, which have been successfully used in 
tracking long-range projection axons and sparse cell populations throughout whole brains in 
rodents or human brain sections26,33–38, or adapted to mapping the cellular organization and 
innervation of peripheral whole organs in mammalian tissues14,23,26,39–41. These heavily 
automated imaging systems are not readily available to biology and clinical laboratories with 
limited resources and budgets. Conversely, traditional histology relies on the irreversible 
sectioning and manual reconstruction of successive slides for image analysis, which is time-
consuming and potentially loses molecular information and connectivity in the process. 
PACT, PARS and RIMS enable deep imaging of large tissue samples without sectioning and 
reconstruction. Antibody expense aside, these cost-effective techniques generate detailed 3D 
reconstructions of intact circuits using only mainstream single-photon microscopy.
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 Experimental design
The procedure comprises seven main stages: tissue preparation (Steps 1–5); formation of a 
tissue-hydrogel matrix (Step 6); tissue clearing (Steps 7 and 8); staining (Step 9, optional); 
enhancement of optical clarity using RIMS (Steps 10–13); imaging (Step 14); and image 
visualization and analysis (Steps 15–17). Although PACT and PARS, including their 
respective tissue-specific variations (PACT-deCAL, PARS-CSF18), each follow the same 
main stages, the decision to proceed with PACT or PARS is generally made before 
commencing the procedure. If the primary goal is to stabilize soft and/or amorphous samples 
(e.g., thymus, spleen, pancreas) for experimentation and sectioning, and not to enhance 
tissue transparency for imaging, users may process samples according to Steps 1–6 (PACT 
or PARS), and with the option to include bis-acrylamide and/or paraformaldehyde (PFA) in 
the PACT hydrogel formulation for increased sample rigidity.
 Required expertise—Most steps of the procedure can be performed by all members of 
the research community. Aspects of the PARS setup (Steps 1–5) require that the scientist be 
approved for working with laboratory animals and/or possess the surgical dexterity to 
establish an intravascular route for delivery of PARS reagents. For example, to execute 
PARS-based clearing of whole laboratory animals (e.g., rodents, nonhuman primates) via 
transcardial perfusion or cannulation, the researcher should be proficient in conducting 
animal euthanasia via transcardial perfusion and/or basic animal surgical techniques and 
practices.
As whole-organ and thick-tissue imaging can generate tera-scale data sets, a computational 
or informatics background, although not necessary if relying on commercial software with 
good technical support, is very helpful in managing large data sets (file storage and 
handling) and in performing image analysis (Steps 15–17).
 PACT or PARS?—Without the use of organic solvents, passively clearing and 
immunostaining larger tissue volumes (e.g., whole organs) is prohibitively slow. In terms of 
clearing efficiency, PACT18 (Figs. 1f,g and 2–6; Supplementary Figs. 1–4) is best suited for 
the quick clearing of small tissue sections (e.g., up to 1–3-mm-thick-sectioned organs 
(Supplementary Fig. 1 or tissue biopsies (Fig. 1f,g)). For whole-organ screening or profiling 
tissues throughout the entire organism, PARS greatly accelerates and simplifies the clearing 
process. All hydrogel monomer solutions, wash buffers, buffered detergents and phenotypic 
labels are driven throughout tissue vasculature via a perfusion-based pressure gradient (Fig. 
7), which under whole-mouse or whole-rat PARS clearing renders most organs transparent 
within 4 d (Fig. 8 and Supplementary Fig. 5). To achieve these PARS clearing rates via 
PACT, excised organs would need to be thick-sectioned and processed individually or in 
batches, as for most other tissue-clearing protocols7–17,19,20. Although the PARS setup is 
more involved than PACT, with the PARS tubing and reagent levels requiring attentive, daily 
monitoring, all organs are processed simultaneously and cleared rapidly and consistently via 
a single perfusion line. In addition, the basic PARS system can be obtained through the 
repurposing of common laboratory items (Fig. 7) and standard protocols (transcardial 
perfusion) within biomedical research.
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 Tissue stabilization by the formation of a tissue-hydrogel matrix—In 
unstabilized tissue, the prolonged incubation in detergent at 37 °C required for PACT and 
the perfusive force used in PARS would be detrimental to tissue integrity. Thus, the 
hybridization of amine-containing and PFA-cross-linked biomolecules to a hydrogel scaffold 
serves to stabilize tissue architecture and nonlipid content throughout all aspects of PACT 
and PARS tissue processing. During PARS, the rodent's intact connective tissue and 
inflexible skeleton provide an additional degree of structural support. To support rapid 
delipidation in the absence of potentially tissue damaging electrophoretic clearing (ETC)24, 
the composition of the PARS/PACT18 hydrogel monomer solution bares a few major 
changes from our originally proposed CLARITY hydrogel8, which consisted of 4% (wt/vol) 
acrylamide, 4% (wt/vol) PFA and 0.05% (wt/vol) bis-acrylamide (A4P4B0.05). First, the 
cross-linker bis-acrylamide must be excluded from the PARS hydrogel formulation to 
prevent hydrogel blockages in vasculature and perfusion lines. Its exclusion from the PACT 
hydrogel as well, and the reduced exposure of tissues to PFA in both protocols, accelerates 
clearing and immunolabeling steps. With a final composition of 4% (wt/vol) acrylamide and 
0% PFA (A4P0), the resulting minimal polymeric scaffold of the PARS and PACT tissue-
hydrogel matrices suffices not only to retain tissue proteins (Fig. 3a and Supplementary Fig. 
2) and stabilize tissue macrostructure18 during clearing, but it also allows SDS micelles to 
diffuse more freely through tissue for efficient clearing (Figs. 4a and 8; Supplementary Fig. 
2c). Similarly, a lower cross-link density ensures that antibodies can better access tissue 
epitopes during immunolabeling (Fig. 4b–d and Supplementary Fig. 3e).
 Tissue clearing—Traditionally, tissue clearing protocols have aimed to render samples 
transparent via homogenizing the RIs of the various tissue components, and matching their 
RIs with the lens and mounting setup (e.g., glass coverslip interfaces). This has often been 
accomplished via exchanging the aqueous fraction of tissue (RI ~1.33) with a mounting 
medium of higher RI, which includes organic solvents such as BABB (RI ~1.53–
1.57)13,14,42, dibenzyl ether (RI ~1.56)12,23, methyl salicylate (RI ~1.52–1.54)43 and 
2,2′thiodiethanol (RI ~1.52)44; polyol and saturated sugar solutions such as glycerol (RI 
~1.43–1.47)8, sucrose and fructose (RI ~1.49–1.50)7,22; and amides such as formamide (RI 
~1.44)10 and urea (RI ~1.38)9,11. Aside from passive CLARITY15 and PACT18, few passive 
clearing protocols endeavor to alter the chemical composition of tissue, by removing major 
tissue components from samples so that they become less light-scattering (see `Chemical 
clearing' in Table 2). One notable example is CUBIC11,21, which also combines the use of 
passive delipidation and RI matching to achieve transparency. Thus, we sought to compare 
the level of delipidation that was achieved with PACT-based clearing (A4P0 and A4P4 
hydrogels) and CUBIC-based clearing. To examine the efficacy of tissue delipidation, we 
used transmission electron microscopy (TEM; Fig. 5b and Supplementary Methods). Indeed, 
as illustrated by membrane permeabilization and extraction, lipid removal was noticed in all 
conditions, and it was highest in A4P0, in which a high degree of fine structure loss is 
evident. In contrast, A4P4 tissue, although extracted, still retains enough contrast for 
identifying fine structural detail, such as membrane-bound organelles and small neurites. 
With respect to structural preservation, the CUBIC samples are between the two PACT 
conditions, showing nearly complete lipid extraction but with some cytoskeletal elements in 
the axon preserved. Although samples embedded in A4P0 hydrogel showed adequate protein 
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and nucleic acid retention for imaging endogenous fluorescence (Fig. 5c) and detecting 
myelin-binding proteins (Fig. 5d), if an enhanced level of tissue preservation is desired it is 
best to embed samples in a hydrogel with a higher order of tissue cross-linking by including 
PFA (for example, by adding 1–4% (wt/vol) PFA to the 4% acrylamide hydrogel solution, 
termed A4P1-4). Alternatively, samples can be processed in parallel, and adjacent areas can 
be directed either to TEM or to hydrogel-embedding and clearing to obtain both 
ultrastructural and volume information, respectively.
The denaturing anionic detergent sodium dodecyl sulfate (SDS), used for lipid removal in 
PACT/PARS, is also very effective in dissociating DNA from proteins (e.g., for cell nuclei 
removal) and in disrupting extracellular matrices to facilitate protein removal (e.g., ionic 
interactions of SDS with membrane proteins allow for their removal and purification). For 
example, retrograde perfusion of a cadaveric rat heart with 1% (wt/vol) SDS for 12 h results 
in its complete decellularization45. By contrast, SDS solubilization of lipid bilayers via a 
micellar mechanism is a slower process. Thus, to guard against the extraction of peptide and 
nucleic acid content during SDS clearing, it is important that nonlipid tissue components 
have been hybridized to a hydrogel scaffold.
In the initial Nature paper describing CLARITY8, the dense tissue-hydrogel cross-linking 
conferred by A4P4B0.05 tissue embedding prohibited rapid passive clearing of large tissue 
blocks24. The advanced CLARITY protocol15 suggests decreasing acrylamide 
concentrations to as low as 0.5% (A0.5P4B0.0125) when clearing is performed passively 
rather than with ETC-based rate enhancement. After the initial, thorough perfusion-fixation 
step with 4% PFA, PACT and PARS tissues are infused with A4P0 monomer18. Although 
bis-acrylamide may be included in the hydrogel formulation to stabilize fragile samples, we 
have not found the addition of bis-acrylamide to be beneficial in preventing protein loss 
(Fig. 3a) in either A4P0-hybridized (A4P0B0.05) or A4P4-hybridized (A4P4B0.05) tissues. 
Furthermore, although protein retention is similar for all A4P0-4 formulations (Fig. 3a), 
higher concentrations of PFA, which anchors tissue to the hydrogel mesh and increases 
tissue cross-linking, result enhanced fine structure preservation (Fig. 5b) and limits 
anisotropic tissue-hydrogel expansion (Fig. 3b,c). The resulting less-porous tissue-hydrogel 
matrix curtails protein solubilization by SDS (Fig. 3a and Supplementary Fig. 2b); clearing 
speed (Fig. 4a and Supplementary Fig. 2c), overall tissue transparency (Fig. 4a) and the 
efficiency of antibody labeling (Fig. 4b–d) are all reduced. Thus, PFA-containing hydrogel 
formulations are only recommended for samples that will be used for in-depth profiling of 
fine structures, in which protein and nucleic acid retention is of maximum importance.
 The importance of pH and temperature in clearing—Here we describe two 
modes of detergent-based tissue clearing: passive lipid removal (PACT: Step 6A for 
hydrogel permeation and embedding, Step 7A for PACT clearing) and active delipidation 
(PARS: Step 6B for hydrogel perfusion and embedding, Step 7C for PARS clearing). Several 
factors, including the chemical properties of the detergent solution, the pH of the detergent 
solution46 and the tissue components to be extracted (i.e., peptide, lipid and nucleic acid), 
affect micelle formation and composition, and hence the clearing efficiency. The role of pH 
is heightened in scenarios, such as tissue clearing, in which relatively high SDS 
concentrations (4–8% (wt/vol) SDS) are used. A slightly basic clearing solution will help to 
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counteract proton buildup at the negatively charged surface of SDS micelles47. Conversely, a 
clearing solution that becomes too acidic has the potential to impair lipid extraction by 
disrupting the structure of the ionic micelles, as well as to encourage protein extraction via 
their denaturation and release from membranes. For these reasons, and to avoid damage to 
tissue and to endogenous fluorescent proteins48, it is important to maintain a physiological 
to slightly basic pH during tissue clearing. Among the alkaline buffers that are best suited 
for PACT and PARS are 0.2 M boric acid (pH = 8.5) and 0.01 M PBS (pH = 7.5 (ref. 18) and 
8.5), with the more basic 8% (wt/vol) SDS solutions offering a slight rate enhancement to 
delipidation (Supplementary Fig. 2c).
Temperature represents a second important factor that influences the solubilization process, 
and, in particular, the micellular composition49. For SDS in aqueous medium, the average 
micelle volume decreases, but the total number of micelles increases as the temperature 
rises50. It is hypothesized that smaller micelles may more readily diffuse through the tissue-
hydrogel matrix, and thus increasing the temperature of the clearing bath will accelerate 
lipid extraction. Higher temperatures (~50 °C), which may enhance clearing efficiency7,15, 
will promote protein denaturation, which has the potential to damage relevant protein 
epitopes or to incur fluorescent protein signal loss. Thus, both PACT and PARS clearing 
steps are performed at 37 °C. To accelerate lipid extraction, the concentration of SDS is 
raised from 4% to 8% (wt/vol) SDS relative to CLARITY, which has a similar effect as 
raising the clearing temperature.
 Labeling—PACT- and PARS-prepared tissues are amenable to most standard 
histological techniques, including those that use immunohistochemical, small-molecule and 
fluorescent protein–based labels, as well as bright-field stains. Small-molecule dyes such as 
nuclear stains rapidly distribute throughout thick tissue sections, such that hour-long to 
overnight incubations are sufficient for most samples. The slow diffusion of full-format 
antibodies (150 kDa) through thick samples, and their tendency to denature and degrade 
over time, necessitates the use of, on average, tenfold more concentrated antibody dilutions 
in primary and secondary incubations of thick sections than in 40-μm-thin sections. The use 
of smaller antibody formats (fragment antigen-binding (Fab): 55 kDa, Fab dimer (F(ab′)2): 
110 kDa,) for secondary antibody labeling is suggested, particularly given their commercial 
availability. Herein, we can achieve adequate labeling of 1-mm-thick sections by Fab format 
antibodies within 48 h. Even smaller formats, most notably camelid nanobodies (15 
kDa)51,52, are ideally suited for labeling thick tissue (Supplementary Fig. 6), as at 10× 
smaller than full IgGs they penetrate tissue rapidly and thoroughly. In addition, their stability 
(e.g., over a wide pH range, at high concentrations, and at temperatures of up to 90 °C) and 
protease resistance allows them to remain intact throughout long incubations conducted at 
room temperature (RT, 18–25 °C) (Supplementary Fig. 6b).
 Enhancement of optical clarity—Infusing and mounting cleared tissues in RIMS 
helps to minimize the mismatch between the RIs of the sample and the microscope 
objective. This so-called optical clearing, which is detailed in Steps 10–13, greatly enhances 
the optical clarity of cleared samples (Figs. 1a–e, 2b, 4, 5a,c,d, 6a and 8; Supplementary 
Figs. 3, 5 and 6b). One could substitute a different mounting solution for RIMS (e.g., sRIMS 
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(Fig. 1f,g), cRIMS, glycerol dilution, FocusClear24, Cargille Labs optical liquids15 and 2,2′-
thiodiethanol44). Optionally, one could measure the RI of the chosen mounting medium 
using a refractometer, dilute glycerol with ddH2O to the same RI, and then use this glycerol 
dilution as the immersion medium for dipping objectives.
 Imaging—To use tissue clearing to its best advantage, the microscope setup must be 
capable of acquiring high-resolution image stacks through thick, cleared samples. Of utmost 
importance are the detection optics. A high numerical aperture (NA ~1.0) and long-working 
distance (w.d. = 5–10 mm) objective will provide high resolving power even when viewing 
deep tissue structures. In addition, as objectives are designed according to the optical 
properties of a target sample and sample mount, an objective that has been optimized to the 
RI range of the RIMS-mounted tissue and immersion medium (RI ~1.46–1.49) will 
minimize spherical aberrations, maximize lateral and axial resolution and help preserve 
fluorescent signal intensity while imaging through thick, cleared tissues. To this end, 
numerous manufacturers have developed specialized multi-immersion and air objectives that 
are well suited to imaging PACT- and PARS-cleared fluorescent samples at depth: e.g., 
Olympus 10× 0.6 NA UIS2-XLPLN10XSVMP and 25× 1.0 NA UIS2-XLSLPLN25XGMP 
objectives (w.d. 8.0 mm) for samples with RI ~1.33–1.52 and RI ~1.41–1.52; Leica HC 
FLUOTAR L 25× 1.0 NA IMM motCORR VISI (w.d. 6.0 mm) for samples with RI = 1.457; 
Zeiss Scale-optimized 20× 1.0 NA objective (w.d. 5.6 mm) for samples with RI = 1.38; and 
Zeiss CLARITY/CUBIC-optimized EC Plan-NEOFLUAR 5× 0.16 NA objective and LSFM 
clearing 20× 1.0 NA objective (w.d. 5.6 mm) for samples with RI = 1.45.
Imaging cleared tissues via two-photon or confocal microscopy can generate extremely 
high-resolution data sets. However, these imaging modalities are time-consuming, 
particularly when scanning a large field of view at depth. Light-sheet fluorescence 
microscopy (LSFM) permits rapid scanning through comparatively large sample volumes, 
which alleviates the imaging bottleneck that can occur with the high-throughput preparation 
of cleared samples. In addition, because image acquisition requires only brief plane 
illumination, LSFM minimizes sample photobleaching, a major drawback in using point-
scanning confocal systems to image large fluorescently labeled samples. Given the 
widespread availability of confocal microscopes but the obvious benefits of LSFM, we 
provide imaging guidelines for each system, as well as design schematics for a cost-efficient 
LSFM system (Fig. 9).
 Data analysis—Following on the heels of the `OME' focus of the past few decades53 
and spurred by the efforts of the BRAIN Initiative (http://www.braininitiative.nih.gov/
index.htm), the Human Brain Project (https://www.humanbrainproject.eu) and the Allen 
Brain Institute, the quest to map the human connectome has recently taken center stage. It is 
unlikely that the connectome project can be tackled by a select few taking a top-down 
approach, as was possible in the elucidation of the human genome54,55. Instead, by tasking 
multiple groups with mapping discrete neural circuits, one can envision the draft of a 
connectome gradually emerging through stitching together these individual wiring diagrams 
(e.g., http://www.openconnectomeproject.org)56–58. When combined with long-working-
depth objectives and high-throughput imaging (LSFM, e.g., CLARITY optimized light-sheet 
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microscopy15; and the custom-made, economical system presented here in Fig. 9, 
Supplementary Table 1, and Supplementary Data 1 and 2), PACT and PARS provide a 
means for efficiently acquiring information on the spatial position of neurons within large 
tissue volumes at high resolution. For this information to be applied to mapping the 
connectome59, however, these gigabytes or even terabytes of raw image data (e.g., for a 
whole mouse brain at 25× magnification) must be converted into a complex network of 
neuron projection pathways and neural contacts, a feat that poses substantial demands on 
both storage hardware and image analysis software. Many available software tools and 
image file formats were not designed with tera-scale data sets in mind and assume that entire 
image volumes fit in computer RAM.
To this end, we have evaluated a range of software packages for processing, visualization 
and analysis of cleared brain volumes, including both general image processing platforms 
and more specialized tools focused on stitching or filament tracing. Table 3 includes a 
summary list of those tools that we found to be stable, functional, user-friendly and well 
supported. For general image analysis, we recommend Fiji60 (a distribution of ImageJ61) and 
Vaa3D62,63, which are open-source, extensible platforms for image analysis and 
visualization that have a rich collection of plug-ins for carrying out specific tasks including 
stitching and fiber tracing64–66. We recommend neuTube67 for semiautomated tracing of 
neurites (Fig. 10a and Supplementary Fig. 7a; see Supplementary Data 3 for the raw 3D 
image stack from which the neuTube traces were generated). Commercial software packages 
Imaris (Bitplane) and Neurolucida68 provide similar functionality, currently offer better 
support for very large image files and can be more stable and user-friendly (Fig. 10b and 
Supplementary Fig. 7b; see Supplementary Data 3 for the raw 3D image stack from which 
the Imaris traces were generated)—making them a good starting point for laboratories with 
less image-processing expertise.
 Image stitching—Confocal and light-sheet microscopes equipped with motorized 
stages usually support tiled acquisition, which is essential for imaging large volumes at 
cellular resolution. These tiles can then be aligned to pixel accuracy and blended together 
using microscope acquisition software such as Leica Application Suite (Leica 
Microsystems), Zen (Zeiss), cellSense (Olympus) and NIS Elements (Nikon Instruments), or 
manipulated off-line using open-source tools such as the TeraStitcher69, the Vaa3D iStitch 
plug-in70, the ImageJ stitching plug-in71, and XuvTools72.
When stitching together multiple tiles, systematic variations in brightness across the image 
field caused by nonuniform illumination, vignetting or imprecise optical alignment often 
result in significant variations in image brightness that can make downstream visualization 
and processing difficult. One solution is to capture smaller tiles from the central field of 
view where illumination tends to be more uniform. However, this increases capture time, as, 
for example, reducing the field of view to the center one-third requires capturing and 
stitching nine times as many tiles. An alternate approach is to directly measure the 
illumination profile using a uniform calibration slide (e.g., see protocols73 and `How flat is 
your confocal illumination profile? Want to find out?' at http://www.spectral.ca/Downloads?
f=2745809748.pdf) or CIDRE74, and then to apply the estimated correction to each acquired 
image tile. This so-called `flat field' or shading correction from a reference image is often 
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supported by acquisition software such as the μManager MultiChannelShading plug-in (see 
http://nic.ucsf.edu/dokuwiki/doku.php?id=flatfieldimageacquisition and ref. 75), shading 
reference in NIS Elements (Nikon Instruments), Leica Application Suite (Leica 
Microsystems), Zen (Zeiss) and cellSense (Olympus), or it can be carried out using an off-
line workflow such as with the ImageJ ImageCalculator; see `How to correct background 
illumination in bright-field microscopy' by G. Landini at http://imagejdocu.tudor.lu/
doku.php?id=howto:working:how_to_correct_background_illumination_in_bright-
field_microscopy.
 Visualization—Image stacks can be visualized using commercial software such as 
Imaris (Bitplane), Amira (FEI), MetaMorph (Molecular Devices) and others (Zen (Zeiss), 
Leica Application Suite (Leica Microsystems), NIS Elements (Nikon Instruments), 
cellSense (Olympus), MetaMorph (Molecular Devices), Volocity (PerkinElmer), Huygens 
(SVI), Arivis Vision4D (Arivis), or using free or open-source tools such as Fiji 3D Viewer76, 
Vaa3D62, Icy77, BioImageXD78, VolView (Kitware, see http://www.kitware.com/
opensource/volview.html) or Bioview3D79. These tools all support 3D volumetric rendering 
of image data that can be interactively rotated and zoomed by the user, as well as 
functionality for selecting subvolumes, virtual 2D sectioning, image contrast and other 
colormap adjustments and manual annotation. Here we provide example workflows and 
estimated processing times based on tests with a large tiled image, 144 fields of view taken 
on an LSM 780 at 5× magnification, stitched in ZEN (Zeiss) to produce a single channel, 8-
bit, 30-GB image stack of size 3.3 × 1010 voxels (16,384 × 9,216 × 220) covering ~1.165 
mm3 (2.72 × 1.53 × 0.28 mm) of tissue.
Stitching very large acquisition volumes can easily produce image files that are too slow to 
load and display directly on machines with limited memory. Table 3 indicates which 
software tools support `out of core' visualization, using read on demand, caching and 
multiresolution representations to process and visualize data sets that are too large to fit in 
memory while preserving interactivity. In particular, TeraFly69, Imaris (Bitplane) and 
BigDataViewer80 (Fiji, see http://fiji.sc/BigDataViewer) use custom multiresolution, tiled 
file formats for storing image data on disk. This aids interactive visualization (even on 
machines with substantial amounts of RAM), as low-resolution views can be displayed 
quickly with higher-resolution detail filled in as soon as it can be read from disk.
 Morphometric analysis—Tracing of neurites can be carried out using plug-ins 
provided in general processing tools such as Imaris Filament Tracer (BitPlane), Amira 
Skeletonization plug-in (FEI), Metamorph NX Neurite Tracing (Molecular Devices), Fiji 
Simple Neurite Tracer64,81 and Vaa3D-Neuron266. Alternatively, one can use special-
purpose software such as Neurolucida68, neuTube67, Neural Circuit Tracer82, 
flNeuronTool83, Farsight trace editor84, Neuron Studio84 and Neuromantic85. Several of 
these tools provide automated or semiautomated workflows that allow a user to trace 
neurites by clicking on a few points along a given neurite, which can greatly accelerate 
initial tracing of long-range projections. The 3D Image Analysis workflow below gives 
estimates of time required to produce a rough-draft trace for a test image (Supplementary 
Data 3). Semiautomated tracing tools are computationally intensive and currently have slow 
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performance on volumes larger than a few gigabytes. Efficient use of these tools thus 
requires manual selection or cropping of regions of interest (ROIs) during annotation, and 
the resulting traces need to be merged in a post-processing step.
Morphology of traced neurites can be saved in SWC (a standard file format developed by the 
Southampton Neurosciences Group; see the SWC file format specifications on the 
Computational Neurobiology and Imaging Center of the Mount Sinai School of Medicine 
website: http://research.mssm.edu/cnic/swc.html), NeuroML86 or NEURON .hoc file 
formats, which in turn can be used with a wide range of downstream neuroinformatics 
tools87,88 including statistical morphometry (e.g., Scorcioni et al.89), assembly and 
simulation of biophysical models (e.g., Gleeson et al.90) and deposition in online searchable 
databases (e.g., http://www.neuromorpho.org/ (ref. 91)).
 Applications of the method
PACT, PARS and RIMS clear a variety of tissues, from laboratory mice and rats (organs and 
adult whole bodies) to primates (Fig. 1f,g, tumor biopsy18), and they are compatible with 
endogenous fluorescence, immunohistochemistry, long-term sample storage18, smFISH and 
microscopy with cellular and subcellular resolution18. Furthermore, the potential exists to 
apply PARS to the clearing and staining of large, isolated whole organs when the vasculature 
is preserved during organ excision92,93. Akin to paraffin embedding, the increased rigidity of 
hydrogel-embedded, uncleared samples may allow unstructured soft tissues (e.g., pancreas, 
thymus) and amorphous biological samples (e.g., sputum) to be stabilized for manual 
sectioning, as well as for automated slicing and imaging systems, such as serial two-photon 
tomography29,37. When these tissue-hydrogel hybrids are cleared with PACT or PARS rather 
than thin-sectioned for imaging, whole organs and thick tissue blocks become amenable to 
visualization with modern microscopy methods such as LSFM (which rapidly scans large 
sample volumes, thereby minimizing photobleaching but maximizing the phenotypic content 
within the image stack) and super-resolution microscopy29,37. Bridging these microscale and 
nanoscale imaging modalities, the recent method of expansion microscopy (ExM)94 recruits 
a by-product of CLARITY8 and PACT18 hydrogel-embedding, namely the capacity to 
absorb water, to great advantage. By deliberately swelling tissue-hydrogel hybrids, 
isotropically expanded tissues can be mined for qualitative information of subcellular 
structures at synaptic resolution using only a conventional confocal microscope.
 Accelerating biomedical discovery with tissue clearing—The current and 
potential biomedical applications of PARS and PACT are summarized in Table 1. PARS and 
PACT enable detailed structural information from peripheral tissue and organ samples to be 
obtained, aiding in the study of distinct cellular populations or environments within their 
unsevered tissue milieu. For example, stem cell niches embedded within relevant tissue 
environments, such as small intestinal crypts95,96 and the bone marrow97, can be studied. 
Tumor architecture and morphology can be mapped98, including tumor margins, tumor 
vascularization, cellular heterogeneity and metastatic foci across the entire organism, for 
both research and diagnostic purposes. Whole-body optical clearing by PARS and imaging 
could facilitate obtaining better peripheral nerve maps39,99, which can then facilitate an 
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understanding of the neural processing that accompanies peripheral nerve/organ function 
and dysfunction41.
Importantly, PARS may also facilitate whole-body screening of therapeutics for off-target 
and on-target binding, and for imaging the biodistribution of administered agents as a 
method for the qualitative determination of their pharmacokinetic–pharmacodynamic 
(PK/PD) properties. Similarly, PARS can be used to expedite the slow, labor-intensive 
process of screening novel viral vector variants for specific tropism characteristics. 
Typically, researchers perform conventional tissue slicing and histology on numerous tissues 
across multiple samples, which is an exceedingly laborious process. Whole-body screening 
through PARS can improve throughput and reduce the risk of sampling errors.
The described protocols for tissue stabilization and lipid removal allow for rapid 
phenotyping of whole organs and whole organisms, and therefore they could advance 
biomedical research with respect to the study of changing tissue pathology during aging or 
during disease progression. One obstacle to studying the progression of cell death that 
occurs during neurodegeneration (e.g., in Parkinson's disease, Alzheimer's disease, epilepsy, 
stroke) is the inability to visualize cells that have already died and have been removed by 
macrophages before the tissue was dissected for histological analysis. A similar cellular 
mapping confound exists in ablation experiments, wherein toxins are used to damage cells 
for studies that aim to causally link the function of a defined neuronal population (compact 
or sparsely distributed) to brain activity and behavior. The postquantification is rarely 
accurate, as it relies on inferring the exact distribution of ablated cells on the basis of their 
representative distribution in placebo-treated brains. By combining PARS with 
TEMPEST27—a precursor to CLARITY—the in vivo expression of long-lasting keratin 
filaments (that outlive the cells themselves while keeping a loyal blueprint of the 
morphology) within populations of interest can facilitate accurate postmortem quantification 
and brain-wide mapping of long-degenerated cells.
 Size fluctuations in tissue-hydrogel hybrids: challenge and opportunities—
Most protocols that render tissues transparent cause notable sample volume fluctuations. In 
general, clearing protocols that entail dehydration steps for clearing with organic solvents or 
some concentrated RI-matching solutions cause tissue shrinkage, whereas protocols that 
involve prolonged incubations in aqueous detergent-based solutions tend to cause gradual 
tissue expansion (Table 2)7,9,22,100. In part a consequence of the water-absorbing properties 
of polyacrylamide, a nitrogen-containing derivative of the super-absorber polyacrylic acid, 
tissue-hydrogel expansion has previously been reported with CLARITY and PACT-
processing8,18 (Fig. 3b,c), and indeed it has been used to great advantage in ExM94. Several 
factors have been shown to influence the swelling properties of water-absorbing hydrogels. 
The most notable are pH; the dissolved ion content of the aqueous swelling medium (i.e., 
clearing buffer) and the tissue-hydrogel microstructure, including the ordering of monomeric 
units within a polymerized hydrogel; the degree of cross-linking; and the mechanical rigidity 
of the embedded tissue. With respect to tissue clearing, as detergent gradually solubilizes 
and extracts tissue biomacromolecules, not only can water migrate into this additional space 
in the tissue-hydrogel matrix but also there is less mechanical resistance from tissue 
components to polymer swelling as water continues to diffuse in.
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For neuron tracing and brain mapping purposes (i.e., connectomics101, expansion-
contraction cycles should be minimized so as not to sever fine processes, distort the spatial 
arrangement of cells within local niches or alter cellular connectivity7. Similarly, gross size 
changes, particularly when anisotropic, complicate image registration with existing atlases 
such as the Allen Brain Atlas102 We have previously proposed a few modifications to 
passive CLARITY-based protocols in order to counteract tissue expansion that occurs during 
clearing and to minimize the occurrence of morphological artifacts that could be introduced 
with fluctuating tissue size7,9,100 They include using in-skull clearing protocols (e.g., PARS-
CSF18 and PARS, see Figs. 7 and 8; Supplementary Fig. 5); extending the postfixation step 
for perfused, excised organs, including the brain, before the start of any clearing protocol; 
and/or performing PACT with a hydrogel monomer formulation that contains increasing 
amounts of PFA (e.g., a hydrogel solution of 4% (wt/vol) acrylamide and 1–4% (wt/vol) 
PFA, A4P1–4)). With respect to the latter, the inclusion of PFA in hydrogel monomer 
compositions not only combats hydrogel swelling but also the expansion becomes 
increasingly isotropic (Fig. 3b). Thus, for improved tissue preservation, it is advisable to 
supplement the A4P0 hydrogel recipe with PFA (1–4% PFA in the monomer solution).
The inclusion of PFA in monomer solutions also curtails tissue size changes in mounting 
medium. Upon their initial immersion in RIMS, tissue samples contract during the first hour 
(~20% for A4P0-embedded coronal rodent brain sections), followed by a gradual rebound 
back to their pre-RIMS size. Imaging during this time window should be avoided, as these 
slight size fluctuations could introduce apparent tissue deformities or sample drift issues 
during image acquisition. With adequate equilibration in RIMS (e.g., hours to days, 
depending on sample size, tissue permeability and so on), sample size and transparency will 
reach a steady state for high-resolution, deep imaging18.
It follows that a motivating factor behind the development of PARS was to neutralize this 
potential risk of tissue expansion during clearing. Although the tissue becomes more 
permissive to hydrogel swelling as lipid membranes are permeabilized and extracted, the 
skin encasing, bone structure and connective tissue will continue to restrict water absorption 
by the hydrogel and thus minimize size changes of the internal organs. Consequently, the 
addition of PFA to the PARS monomer solution is not necessary.
However, swelling—if isotropic—can be advantageous. By expanding hydrogel-embedded 
tissue uniformly, dense cell populations can be distributed spatially for cell counting or for 
analyzing local cell contacts (Supplementary Fig. 4 and Supplementary Methods); similarly, 
dense cell and/or fiber tracts, such as the corpus callosum, the spinal cord and individual 
muscles, may be expanded for easier anatomical study. For example, ExM recently recruited 
the swelling properties of CLARITY tissue-hydrogel hybrids8,18 to visualize samples at 
nanometer resolution94 Through altering the monomer components and concentration, 
scientists may quickly adjust the overall volume occupied by the hydrogel-embedded 
tissues, shrinking tissues to fit within the working distance of an objective or swelling tissues 
for facile high-resolution imaging of diffraction-limited spots103 Such measurements require 
separate validation with well-established super-resolution microscopy methods104–108 until 
one can confirm that specimen preparation does not introduce anisotropic distortions.
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 Limitations of the method
As discussed in the previous section, some tissue deformation is expected with all tissue 
clearing protocols (see examples in Table 2), wherein the tendency for tissue to expand 
and/or shrink moderately during sample clearing and/or mounting is frequently noted7,8,10. 
Whether these volume changes cause structural damage that would confound the 
interpretation of sample images is widely debated. Although we have observed some tissue 
swelling during PACT and PARS clearing, tissues subsequently contract to approximately 
their original size in RIMS medium. Although it is difficult to test exhaustively by individual 
efforts, the net impact of these changes on overall cellular architecture appears to be 
minimal, as demonstrated by the preservation of fine cellular morphology across a range of 
tissue types18. However, such changes in tissue volume could complicate image registration. 
To compare an image stack of an experimental sample with a representative data set or with 
a reference atlas, it will be necessary to use structural landmarks or tissue stains rather than 
the sample size to align images. Validated tissue stains that can help with registration include 
the following: Nissl or Golgi stain for the brain; membrane and organelle stains, including 
the use of lectins to label vascular networks, as well as H&E stain to simultaneously 
visualize hematoxylin-stained nucleic acid and eosin-stained red blood cells, cytoplasmic 
material, cell membranes and extracellular structures and protein; and fuchsin to label 
collagen, smooth muscle or mitochondria. Finally, unstained structural components (e.g., 
distinctive neuron arborization109, large tissue structures110 and cortical surfaces110–112 can 
be imaged at lower resolution to create reference images to aid in registering high-
resolution, small volumes113) and artificial landmarks (e.g., gold-seeding or quantum dot 
deposition114, electron microscopy (EM) platform grids for serial section mounting and 
imaging115) may be used as fiducial markers for registering sample data sets collected 
during light and electron microscopy, as well as for cross-referencing in vivo imaging scans 
with subsequent ex vivo data sets.
To image whole organs or thick tissue sections, the image data file sizes will be tera-scale; 
thus, it is important to use a computational workstation with substantial RAM (this will be 
highly dependent on the individual software requirements, user-specific variables such as the 
average file size and the desired image analysis capabilities). Our experience showed that as 
much as 64–256 GB might be needed, depending on data and analysis type, multicore CPUs 
and an excellent graphics card (e.g., Windows platform: AMD Radeon R9 290X 4.0 GB; 
Mac platform: AMD FirePro D700 6 GB).
 MATERIALS
 REAGENTS
• Sample to be imaged. This protocol describes imaging of brain and body 
samples prepared from wild-type mice (C57BL/6N and FVB/N, both male and 
female), Thy1-YFP mice (line H) and TH-cre rats ▲ CRITICAL Experiments 
on vertebrates must conform to all relevant governmental and institutional 
regulations. Animal husbandry and all experimental procedures involving mice 
and rats were approved by the Institutional Animal Care and Use Committee 
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(IACUC) and by the Office of Laboratory Animal Resources at the California 
Institute of Technology.
• Euthasol (Virbac, cat. no. 710101)
 Perfusion solutions
• Paraformaldehyde (PFA; 16% and/or 32% (wt/vol) PFA in aqueous solution; 
Electron Microscopy Sciences, cat. no. 15710-S)
• 1× PBS
• Sodium nitrite (Sigma-Aldrich, cat. no. 237213-500G) ▲ CRITICAL As a 
vasodilator, 0.5% (wt/vol) sodium nitrite is added to the heparinized saline 
perfusion buffer to facilitate thorough blood removal from vasculature and 
perfusion ease. Alternatively, nitroglycerin may be substituted for sodium 
nitrite.
• Heparin sodium salt from porcine intestinal mucosa (Sigma-Aldrich, cat. no. 
H3149) ! CAUTION PFA is toxic. Perform all procedures in a fume hood.
 Hydrogel monomer solution
• Acrylamide solution (40% (wt/vol); Bio-Rad, cat. no. 161-0140) ! CAUTION 
Acrylamide monomers are toxic. Perform all procedures in a fume hood.
• Bis-acrylamide (2% (wt/vol); Bio-Rad, cat. no. 161-0142) ! CAUTION Bis-
acrylamide monomers are toxic. Perform all procedures in a fume hood.
• Polymerization thermal initiator VA044: 2,2′-Azobis[2-(2-imidazolin-2-yl) 
propane]dihydrochloride (Wako, cat. no. VA-044)
• 10× PBS
 Clearing solutions
• Boric acid (Sigma-Aldrich, cat. no. B7901 or B6768)
• Sodium hydroxide pellets (EMD, cat. no. SX0590-3)
• SDS (Sigma-Aldrich, cat. no. L3771) or 20% (wt/vol) SDS solution in water 
(Sigma-Aldrich, cat. no. 05030)
• 10× PBS ▲ CRITICAL We have successfully used either `homemade' PBS or 
PBS from a variety of suppliers.
• 0.5 M EDTA solution (Lonza AccuGENE, cat. no. 51234; or Sigma-Aldrich, 
cat. no. 03690)
 Refractive index matching solution (RIMS)
• Histodenz (Sigma-Aldrich, cat. no. D2158)
• Phosphate buffer, 0.02 M
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• Sodium azide (Fisher Scientific, cat. no. 71448-16) ! CAUTION To prevent 
microbial growth, sodium azide should be added to all mounting media (RIMS 
and sRIMS), as well as to all immunostaining dilutions and wash buffers that 
are used in extended incubations. As a stock solution, 5% (wt/vol) sodium 
azide in water is highly toxic. Keep sodium azide solid and 5% stock solutions 
away from ignition sources. Store it in a cool, dry, well-ventilated area away 
from incompatible substances. Do not store it in metal containers, and keep the 
storage containers tightly closed. Contact with acids liberates very toxic and 
explosive hydrazoic acid vapor, and some hydrazoic acid may form in aqueous 
solutions prepared with sodium azide. Hydrazoic acid volatilizes readily at 
99 °F; thus, do not autoclave any solutions that are prepared with sodium 
azide. Sodium azide is an eye and skin irritant, it may be highly toxic if inhaled 
or ingested and it is metal-reactive; wear gloves and eye protection when 
preparing stock solutions that contain sodium azide, and do not weigh out solid 
sodium azide using a metal spatula (use plastic instead). ! CAUTION With 
respect to long-term storage, sodium azide is chemically stable. However, it 
will decompose upon heating. Sodium azide waste disposal should be 
conducted according to federal, state and local regulations.
• Sorbitol-based RIMS (sRIMS)
• Sorbitol, 70% (wt/vol) (Sigma-Aldrich, cat. no. 309532)
 Refractive index matching solution for cold storage (cRIMS)
• Histodenz (Sigma-Aldrich, cat. no. D2158)
• 0.005 M phosphate buffer
• Sodium azide (Fisher Scientific, cat. no. 71448-16)
 Immersion medium and alternative mounting medium
• Glycerol (87% (vol/vol)): prepare 80–90% (vol/vol) glycerol (Sigma-Aldrich, 
cat. no. G5516) in dH2O.
 Immunostaining reagents
• 1× PBS with Triton X-100 (0.1% (vol/vol))
• Primary and secondary antibodies (see Table 4 for examples of antibodies used 
in this and related work)
• Normal donkey serum (Jackson ImmunoResearch Laboratories, cat. no. 
017-000-121)
• Agarose, low-melt temperature (Research Products International Corp., cat. no. 
9012-36-6)
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 FISH reagents
• FISH reagents18-are optional (see Supplementary Methods and published 
methods116–119)
• 10× PBS, pH 7.4, RNase-free (Life Technologies, cat. no. AM9625)
• Ethanol, absolute (J.T. Baker, cat. no. 8025) ! CAUTION Ethanol is 
flammable.
• RNase-free sterile H2O (Life Technologies, cat. no. 10977-015)
• Dextran sulfate, 10% (wt/vol)-(Sigma-Aldrich, cat. no. D8906)
• Formamide, deionized, nuclease-free (EMD Millipore, cat. no. 344206; or Life 
Technologies, cat. no. AM9342) ! CAUTION Formamide is a toxic chemical 
and a teratogen; handle it inside a fume hood with appropriate protective gear 
(gloves, goggles, lab coat).
• Saline sodium citrate buffer, 20×, RNase-free (Life Technologies, cat. no. 
AM9763)
• Slowfade Gold + DAPI (Life Technologies, cat. no. S-36938)
• Aminosilane-treated coverslips ((3-aminopropyl) triethoxysilane; Sigma-
Aldrich, cat. no. 440140)
• Sodium borohydride (Sigma-Aldrich, cat. no. 213462; or Santa Cruz 
biotechnology, cat. no. CAS 16940-66-2) ! CAUTION Sodium borohydride is 
highly flammable when in contact with moisture, and it is very toxic to the 
skin. Do not leave the flask uncapped. Prepare dilutions fresh, on ice, in a fume 
hood or in a chemical hood. Close tightly after weighing, seal with Parafilm 
and return the reagent-to its containment canister (if applicable to institutional 
laboratory practices).
 EQUIPMENT
 Hydrogel polymerization
• House vacuum line or vacuum pump
• Nitrogen gas supply (any)
• Polytetrafluoroethylene (PTFE) tubing (McMaster-Carr) and/or Masterflex L/S 
14 tubing (Cole-Parmer), for connection to vacuum line and inert gas supply
 PACT equipment
• Sample vials, either commercially available Vacutainers (10-ml Vacutainer 
serum blood collection tubes; BD Biosciences, cat. no. 366430) or 50-ml 
conical tubes with commercially available rubber stoppers for hydrogel-
embedding step
• Commercially available stoppers for 50-ml conical tubes: folding skirt rubber 
stopper, 30.7 mm diameter (Cole-Parmer, cat. no. EW-62995-87) or Saint 
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Gobain folding skirts rubber stoppers, 31.4 mm diameter (Spectrum Chemical 
Mfg. Corp, cat. no. 142-55179) or Twistit rubber stopper size 6 (Fisher 
Scientific, cat. no. 14-131D; Sigma-Aldrich, cat. no. Z164364; eBay, various)
• Air-Tite Vet premium hypodermic needles, 22-gauge (22-G) × 4 inches, (Air-
Tite Products Co., Lot: 14-11563, SKU N224)
• 1- to 1.5-inch needles for venting sample containers during hydrogel-
embedding (16–22-G)
• 3- to 5-ml syringes (BD syringes)
 PARS equipment
• Masterflex Tygon E-Lab tubing (Cole Palmer, cat. no. EW-06460-48), or 
Tygon S3 laboratory tubing E-3603 (VWR, 0.125 inch inner diameter (i.d.): 
cat. no. 89403-854; 0.09375 inch i.d.: 89404-000)
• Three-way stopcock with Luer lock (World Precision Instruments, cat. no. 
14035-10)
• Luer-to-tubing coupler kit (World Precision Instruments, cat. no. 500895)
• Barbed fitting assortment kit (World Precision Instruments, cat. no. 500890)
• 22-G × 1-inch gavage needle (e.g., 22-G, 1.25-mm-tip-diameter straight 
feeding needle; Fine Science Tools, cat. no 18061-22; Braintree Scientific, cat. 
no. N-PK 002)
• Pipette tip boxes; we use empty 1,000-μl racked filter tip boxes (USA 
Scientific)
• Optional: 20-G blunt needle (BD Biosciences, cat. no. 305183) and tubing 
(PlasticsOne) for PARS-CSF18
• C & B Metabond (Parkell, cat. no. S380)
• Tape (any)
• Modeling clay (e.g., Sargent Art, cat. no. 22-4400)
• Peristaltic pump or circulator (e.g., Cole Palmer Masterflex L/S, cat. no. 
77800-60; or Cole-Palmer Masterflex L/S Easy Load II head and pump drive, 
cat. nos. 77200-62 and 7557-12)
• Freezer bags, 1 gallon (Ziploc, or equivalent reusable and re-sealable airtight 
freezer bags made of durable plastic with a zipper closure)
 General equipment and supplies
• Silicon aquarium sealant (e.g., 3 M marine grade silicone sealant, clear, cat. no. 
PN08019)
• Platform shaker (VWR, rocking platform model 200) and/or nutating mixer 
(VWR, cat. no. 82007-202)
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• Bath incubator (Fisher Scientific, Isotemp model 2223) or 37 °C warm room
• Shaking water bath (Thermo Forma, cat. no. 003-8830)
• Razor blades and/or scissors (any)
• mColorpHast pH test strips (EMD Millipore, cat. nos. 1.09543.0001 and 
1.09584.0001)
 Sample mounting and imaging for confocal microscopy
• Spacers, 7.0 or 3.0 mm (iSpacer, SunJin Lab Co.), or 0.5 mm or 2.5 mm 
spacers (Silicone Isolator, Electron Microscopy Sciences; or GRACE Bio-
Labs), or silicone rubber sheet (any)
• Putty (e.g., Bostik Blu-Tack adhesive putty)
• Clear nail polish or Entellan (Electron Microscopy Sciences, cat. no. 14800)
• Microscope slides (Thermo Scientific, cat. no. 10143352; VWR, cat. no. 
48382-173; Brain Research Laboratories, cat. no. 5075-plus)
• Coverslips (VWR, cat. no. 48404-452, 16004-344, 16004-322; Brain Research 
Laboratories, cat. no. 4860-11/2)
• Vacuum grease (Sigma-Aldrich, cat. no. Z273554)
• Optional: Refractometer (Reichert AR200 digital handheld refractometer, cat. 
no. 13950000)
• Confocal or light-sheet microscope – any, as available; data here were obtained 
with a Zeiss LSM 780 single-photon microscope or a custom-made LSFM 
system (see supplies listed in Supplementary Table 1, immersion chamber and 
sample holder in Supplementary Data 1 and 2, respectively)
• Microscope objectives for thick-section imaging, such as the CLARITY-
optimized objectives now produced by major microscopy companies, including 
Leica and Olympus. Images presented here and in Yang et al.18 were obtained 
using the following Zeiss objectives: Fluar 5×/0.25 M27 objective (w.d. 12.5 
mm), Plan-Apochromat 10×/0.45 M27 objective (w.d. 2.0 mm), LD SC Plan-
Apochromat 20×/1.0 Corr M32 85mm scale-immersion objective (w.d. 5.6 
mm), LD LCI Plan-Apochromat 25×/0.8 Imm Corr DIC M27 multi-immersion 
objective (w.d. 0.57 mm) and Olympus 25× 1.0 NA multi-immersion objective 
(w.d. 8.0 mm)
• Image handling software, such as Imaris (Bitplane)
 REAGENT SETUP
 0.1 M phosphate buffer (PB)—Add 3.1 g of NaH2PO4 (monohydrate) and 10.9 g of 
Na2HPO4 (anhydrous) in dH2O to a total volume of 1 liter at pH 7.4; filter-sterilize the 
solution and store it at RT or at 4 °C for up to several months. For RIMS, dilute the buffer 
fivefold to 0.02 M phosphate buffer, and adjust the final RIMS pH to 7.5.
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 0.01 M PBS (1× PBS)—Combine 8 g of NaCl, 0.2 g of KCl, 1.42 g of Na2HPO4 and 
0.245 g of KH2PO4 in dH2O to a total volume of 1 liter; adjust the pH to 7.4, filter-sterilize 
or autoclave the solution and store it at RT or at 4 °C for up to several months. Alternatively, 
purchase 1× PBS mix (Sigma-Aldrich, cat. no. P5368) or pre-made solution (Lonza, cat. no. 
04-409R) from a commercial supplier; adjust the final pH when necessary. Use 1× PBS at 
pH 7.4 unless otherwise noted (e.g., in clearing buffers).
 10× PBS stock—For 10 liters of the 10× stock, dissolve 800 g of NaCl, 20 g of KCl, 
144 g of Na2HPO4 dihydrate and 24 g of KH2PO4 in 8 liters of dH2O. Add additional water 
to a total volume of 10 liters; filter-sterilize or autoclave the solution. Upon dilution to 1× 
PBS, the pH should approach 7.4. The pH may be adjusted with hydrochloric acid or sodium 
hydroxide, as needed. The resulting 1× PBS should have a final concentration of 10 mM 
PO4, 137 mM NaCl and 2.7 mM KCl. Alternatively, purchase 10× PBS premade solution 
(e.g., Lonza, cat. no. 17-517Q) from a commercial supplier.
 Heparinized PBS (hPBS)—For flushing vasculature of blood at the start of perfusion, 
prepare 1× PBS with 0.5% (wt/vol) sodium nitrite and 10 units per ml heparin, pH 7.4. Place 
it on ice until use or refrigerate it for up to a few weeks.
 4% PFA (for perfusion fixation)—To prepare 40 ml of 4% PFA (wt/vol, final 
concentration), combine 4 ml of 10× PBS, 5 ml of 32% (wt/vol) PFA solution and 31 ml of 
ice-cold water. Adjust the pH to 7.4 and keep it on ice or refrigerate it until use (same day).
 1× PBS containing 0.1% (vol/vol) Triton X-100 (PBST)—Add 1 ml of Triton 
X-100 to 1× PBS for a total volume of 1 liter; adjust the pH to 7.4. PBST may be stored at 
RT for a few months when it is filter-sterilized; vortex or stir the solution on a stir plate for 
several minutes before use.
 Boric acid buffer (BB)—Prepare a 1 M boric acid buffer stock solution by stirring 
61.83 g of boric acid and 10 g of NaOH in 900 ml of water with gentle heating. Once 
sodium hydroxide pellets and boric acid are fully dissolved, adjust the pH to 8.5 with NaOH 
and add water to a total volume of 1 liter; store it at RT for up to a few months. To prepare 
fresh borate-buffered clearing solutions, such as 8% (wt/vol) SDS in 0.2 M BB at pH 8.5 
(8% SDS-BB) for PACT and PARS, dilute 400 ml of 20% (wt/vol) SDS and 200 ml of 1 M 
boric acid buffer stock to 1 liter with distilled and deionized water (ddH2O); adjust the pH to 
8.5, if necessary. To make a boric acid wash buffer (BBT, 0.2 M boric acid buffer with 0.1% 
(vol/vol) Triton X-100, pH 8.5), dilute the 1 M boric acid stock to 0.2 M boric acid in 
ddH2O, adding 1 ml of Triton X-100 per liter of BBT and stirring on a stir plate for 10 min. 
BBT may be stored at RT for several weeks, barring contamination; vortex the solution or 
stir it on a stir plate for several minutes before use.
 PACT monomer solution—For rapid preparation of samples that are amenable to both 
standard immunohistochemistry and fluorescence imaging, as well as smFISH, prepare an 
A4P0 hydrogel: 4% (wt/vol) acrylamide (0% PFA) in 1× PBS. For 200 ml of hydrogel 
monomer solution, add 20 ml of 40% (wt/vol) acrylamide and 20 ml of 10× PBS to 160 ml 
of ice-cold dH2O. Stir 500 mg of thermoinitiator 2,2′-azobis[2-(2-imidazolin-2-
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yl)propane]dihydrochloride into ice-cold monomer solution (0.25% (wt/vol) final 
concentration). Hydrogel monomer solutions must remain cold before use to prevent 
premature polymerization; we generally prepare solutions freshly on ice, but they may be 
stored short-term (several hours) at 4 °C or on ice, or long-term (several months) at −20 °C, 
protected from light. ▲ CRITICAL We have tested various hydrogel monomer 
formulations: including combinations of 2% or 4% (wt/vol) acrylamide with 0% or 4% PFA 
and/or 0.05–0.25% (wt/vol) bis-acrylamide. We found that A4P0 without bis-acrylamide 
granted rapid clearing and good antibody penetration during immunohistochemistry (IHC) 
without compromising the macromolecular content and cellular structure of tissue samples. 
In comparison with CLARITY, we eliminated 4% PFA from the hydrogel monomer 
solution; however, we ensure the thorough PFA-mediated cross-linking of tissue proteins 
before hydrogel monomer incubation via 4% PFA transcardial perfusion and 4% PFA 
postfixation steps. ▲ CRITICAL To enlarge the hydrogel pores for faster sample clearing 
and immunolabeling, we excluded bis-acrylamide and PFA from the hydrogel recipe 
proposed for CLARITY8. Although tissue proteins and overall tissue architecture was 
preserved during PACT and PARS processing18, specific native and non-native biomolecules 
(e.g., non-membrane-associated proteins, cytoplasmic signaling molecules, commensal and 
pathogenic micro-organisms) may be more sensitive to the clearing process. Herein, either 
or both of these hydrogel components may be re-introduced into the hydrogel formulation to 
increase cross-linking density and thus better stabilize sparse epitopes. However, any 
increase in the net concentrations of hydrogel monomers will result in slower diffusion of 
SDS micelles and of antibody-based labels during clearing and immunostaining, 
respectively.
 A4P1, A4P2 and A4P4 monomer solutions—To preserve a sensitive sample's 
structural integrity during clearing, include 1, 2, or 4% PFA (wt/vol, final concentration) in 
the hydrogel formulations (i.e., A4P1, A4P2, and A4P4, respectively). For example, for 200 
ml of A4P4 monomer solution, add 20 ml of 40% (wt/vol) acrylamide, 25 ml of 32% (wt/
vol) PFA and 20 ml of 10× PBS to 135 ml of ice-cold dH2O. Stir 500 mg of thermoinitiator 
2,2′-azobis[2-imidazolin-2-yl)propane] dihydrochloride into ice-cold monomer solution 
(0.25% (wt/vol) final concentration). Hydrogel monomer solutions must remain cold before 
use to prevent premature polymerization; we generally prepare solutions freshly on ice, but 
they may be stored short-term at 4 °C or long-term at −20 °C, protected from light.
 PACT-deCAL—Combine 10 ml of 0.5 M EDTA and 40 ml of 1× PBS; adjust the pH to 8 
and store it at RT for up to a year, barring contamination.
 Detergent for tissue clearing—PACT and PARS tissue clearing is accomplished via 
exposing the tissue to an 8% (wt/vol) SDS detergent solution or, in special cases (PACT-
deCAL, ePACT), to a 10% (wt/vol) SDS detergent solution. All initial validation of PACT 
and PARS was performed using a range of SDS concentrations (4–16% (wt/vol) SDS), 
prepared in a range of buffers (1× PBS at pH 7.5, 1× PBS at pH 8.0 (for PACT-deCAL), 1× 
PBS at pH 8.5 and in 0.2 M sodium borate buffer at pH 8.5). Aside from a slight clearing 
rate enhancement at more alkaline pH (i.e., 8% SDS-BB and 8% SDS-PBS at pH 8.5), there 
was no apparent trade-off in the quality or characteristics of cleared soft tissue. Thus, PARS 
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and PACT tissue clearing in 1× PBS at pH 7.5 (abbreviated 8% SDS-PBS (pH 7.5)) may 
hold added convenience for many users. We suggest periodically replacing the clearing 
solution if it begins to acidify (i.e., monitor the clearing solution pH with pH indicator strips 
every 72 h). For PACT-deCAL, we strongly recommend increasing the SDS concentration 
and clearing solution pH, as both will favor more rigorous and efficient calcium removal; the 
results presented in Figure 6 were obtained using a clearing solution of 10% (wt/vol) SDS in 
1× PBS, with a final pH of 8.0 (abbreviated 10% SDS-PBS (pH 8)). ▲CRITICAL It is 
worthwhile to note that sodium borate buffer possesses antimicrobial and antifungal 
characteristics that make it an ideal buffer for extended tissue incubations. When 1× PBS 
instead of sodium borate is used, an appropriate antimicrobial agent should be added to the 
buffer (e.g., a final concentration of 0.01% (wt/vol) sodium azide in buffer solutions). We 
prepare clearing solutions fresh for each round of tissue clearing, with RT storage (up to 
several weeks) of excess clearing solution for buffer exchanges. ▲CRITICAL Although a 
clearing solution of 8% (wt/vol) SDS is proposed, users may wish to vary the SDS 
concentration according to their needs. As a starting point, lower SDS concentrations should 
be used for larger samples, as this prevents the detergent-exposed outer layers from 
overclearing while the sample center remains opaque. Thinner tissue sections (e.g., 250-μm 
brain slices from electrophysiology) may be cleared rapidly with 10–15% (wt/vol) SDS; 
however, overclearing and loss of biomolecules are a greater risk.
 Antibody incubation buffer (IHC buffer)—The dilution of antibodies used in PACT 
and PARS will be highly dependent on, among other things, the quality of the antibody, the 
size and tissue type of the sample to be labeled, and the cellular location and concentration 
(i.e., expression level) of the target biomolecule. We recommend a starting dilution of 
~1:200–400 and/or staining reagents in 1× PBS containing 2% (vol/vol) normal donkey 
serum, 0.1% (vol/vol) Triton X-100 and 0.01% (wt/vol) sodium azide; however, the exact 
antibody concentrations will need to be validated on a case-by-case basis. Freshly prepare 
IHC buffer.
 RIMS—For a mounting medium with an RI = 1.47 (RIMS-1.47), which is used for all 
samples presented here unless otherwise noted, dissolve 40 g of Histodenz in 30 ml of 
sterile-filtered 0.02 M phosphate buffer. This is most easily accomplished by adding 
Histodenz, phosphate buffer and a magnetic stir bar to the final storage container (e.g., a 
125-ml glass jar with a lid); sealing the container to minimize evaporation and 
contamination; and stirring the solution on a stir plate for ~10 min, vigorously shaking the 
closed jar by hand a few times during the stirring process. Once the Histodenz has dissolved, 
add sodium azide to a total concentration of 0.01% (wt/vol) and adjust the pH to 7.5 with 
NaOH. RIMS may be prepared with a lower or higher RI by varying the final concentration 
(wt/vol) of dissolved Histodenz (Fig. 6b). RIMS may be stored at RT for several months; 
discard it if microbial contamination occurs. Do not autoclave any solutions containing 
sodium azide. ▲CRITICAL There are numerous commercial and home-made RIMS 
alternatives, including FocusClear24, Cargille Labs optical liquids15, 2,2′-thiodiethanol44 and 
diluted glycerol. We have only verified the compatibility of FocusClear and glycerol with 
our PACT and PARS prepared samples, and thus we provide a glycerol-based mounting 
medium recipe here.
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 sRIMS—Prepare a 70% (wt/vol) sorbitol solution in 0.02 M phosphate buffer with 0.01% 
(wt/vol) sodium azide (pH adjusted to 7.5 with NaOH); store sRIMS at RT for up to several 
months, barring microbial contamination. This sorbitol-based mounting medium 
outperforms 80–90% (vol/vol) glycerol as RIMS for rodent brain samples. At a net cost of ~
$0.2 per ml, sRIMS offers the greatest cost advantage over commercial RI matching 
solutions that we have tested, such as FocusClear8, and without a sacrifice in performance.
 cRIMS—Prepare a stock buffer solution of sterile-filtered 0.005 M phosphate buffer. For 
a mounting medium with RI = 1.47, dissolve 40 g of Histodenz in 30 ml of this stock buffer 
solution; this is most easily accomplished on a stir plate (see instructions for RIMS). Once 
the Histodenz has dissolved, add sodium azide to 0.01% (wt/vol) and adjust the pH to 7.5 
with NaOH. cRIMS may be stored at 4 °C for several months, barring microbial 
contamination. Samples that require short-term storage at 4 °C may be mounted in cRIMS, 
whereas RIMS-mounted tissue will become cloudy or turbid placed at 4 °C—the lower salt 
concentration of cRIMS reduces the appearance of salt precipitate at colder temperatures. 
Do not autoclave any solutions that contain sodium azide.
 EQUIPMENT SETUP
 Degassing the container for hydrogel polymerization—Glass Vacutainers work 
well for degassing and hydrogel-embedding small rodent organs and tissue samples. 
However, for rat whole brains and larger tissue samples, a larger container is sometimes 
useful. One solution is to purchase rubber stoppers that are compatible with 50-ml conical 
tubes and replace the conical screw-cap with an air-tight rubber stopper during degassing 
and hydrogel polymerization steps (Fig. 2).
 PARS chamber—To perfuse PARS reagents through vasculature in a contained 
environment, we construct a PARS chamber using components that are readily found in most 
of the biological research laboratories (Fig. 7). The necessary components of a PARS setup 
are as follows: a feeding needle catheter to deliver PARS reagents to vasculature; a perfusate 
catch-basin (pipette box) in which recirculating PARS reagents may pool once they exit the 
vasculature;-Tygon tubing threaded through a peristaltic pump so that pooling reagents may 
be collected from the catch-basin and recirculated back into a subject's vasculature; Luer-to-
tubing couplers; and a Ziploc bag to contain the entire PARS chamber setup.
To construct the PARS chamber, drill two 1/8-inch holes into the front and one 1/8-inch hole 
into the left side wall of an empty 1,000-μl pipette tip box. The holes are drilled just below 
the tip wafer (in Fig. 7, the holes are ~2 cm below the top rim). Next, snap 1/8 × 1/8-inch 
barbed connectors into each of the drilled holes. The outflow line will circulate solvents 
from the pipette box chamber to the 3-way stopcock. To join the outflow line to a 3-way 
stopcock, use a 10-cm piece of Tygon tubing and connect one end to the inner left side 1/8 × 
1/8-inch barbed connector and tape the other end to the inside bottom of the pipette tip box. 
Continue this line through a peristaltic pump by using a new piece of Tygon tubing, and 
connect one end to the outer left side 1/8 × 1/8-inch barbed connector and then thread the 
tubing through a peristaltic pump. Next, join the free end to a three-way stopcock with a 
3/32-inch barbed male Luer with locking nut. The inflow line circulates solvents from the 
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three-way stopcock to the vasculature. To link the inflow line to the pipette tip box, use a 
piece of 15-cm Tygon tubing and connect one end to the outer right front 1/8 × 1/8-inch 
barbed connector and the other end to the three-way stopcock with a 3/32-inch barbed male 
Luer with locking nut. To finish the inflow line, connect a piece of 75-cm Tygon tubing to 
the inner right front 1/8 × 1/8-inch barbed connector. Next, coil the inflow line to the bottom 
of the pipette tip box. This will equilibrate inflowing solvent to the desired temperature 
before it enters the subject's vasculature. Tape the coiled tubing to the pipette tip box. To 
quickly circulate bubbles formed during the changing of solutions without disconnecting the 
inflow line and for use of bubbling nitrogen gas into the solution during the polymerization 
step, a line linking the outflow line back to the pipette tip box is connected by joining a 
piece of 15-cm Tygon tubing to the three-way stopcock with a full-thread 3/32-inch barbed 
female Luer to the outer left front 1/8 × 1/8-inch barbed connector. This line is continued 
inside the pipette tip box and taped to the bottom. To finish the chamber, thread the inflow 
line through the top-left corner of the tip wafer and connect it to a feeding tube with a 1/8-
inch barbed male slip Luer. As a forewarning, SDS and salt precipitate will begin to 
accumulate within these narrow lines over time. It is important to flush the lines (e.g., with 
ddH2O) between subjects, and to replace occluded lines with new Tygon tubing (e.g., after 
every few subjects).
During hydrogel polymerization, the chamber must be enclosed inside a Ziploc freezer bag. 
To do this, disconnect the outer Tygon tubing that connects to the barbed connectors of the 
pipette tip box, and puncture three holes into the Ziploc bag to accommodate the 1/8 × 1/8-
inch barbed connectors. Reconnect the Tygon tubing to their original 1/8 × 1/8-inch barbed 
connector. To connect a vacuum line to this bagged PARS box for withdrawing oxygen, tape 
a female Luer tee onto the lid of the pipette box and puncture one hole through the Ziploc. 
Finally, make the Ziploc airtight by placing clay around the punctured regions in the Ziploc.
As a final note, a 1,000-μl tip box has a volume of ~750 ml. Thus, during hydrogel 
polymerization and during clearing, 200–300 ml of solution may be placed in the pipette box 
for recirculation without risk of the pipette box overflowing or the solution splashing out 
during its transport. Similarly, to conserve reagents during PARS clearing and 
immunostaining of smaller samples, a 200-μl tip box may be used to construct the PARS 
chamber; only 100 ml of reagent is necessary to fill such a chamber about one-third full 
(Fig. 7).
 Light-sheet microscope—The light-sheet microscope that we use was built based on 
the laser-scanning single-side illumination method120. Key to the design are objectives that 
offer a long w.d. while maintaining high NA (e.g., CLARITY objectives with 8 mm w.d. and 
NA of 1.0). The system described below provides a cost-effective and relatively easy-to-
replicate alternative to CLARITY optimized light-sheet microscopy(COLM)15, a recently 
introduced light-sheet microscope for CLARITY. We used cost-effective optical 
components, especially when creating, shaping and projecting the illumination light sheet. 
The immersion chamber and sample holder are custom-made with a 3D printer. The list of 
components and the .stl design files can be found in the Supplementary Table 1 and in the 
Supplementary Data 1 and 2 (.stl format), for the immersion chamber and sample holder, 
respectively.
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The microscope is built onto a 4 × 6-foot optical table (Fig. 9b). The various lasers are 
combined with dichroic filters to one beam, which is then expanded using a Galilean 
telescope and shaped with an iris to match the Galvanometer scanner mirror size (6 mm in 
diameter). The Galvanometer scanner, coupled with an f-theta lens, is then used to generate 
the scanning light sheet, which is projected to the sample holder using two achromatic 
doublet lenses. The resulting light sheet has a full-width-half-maximum of 5–7 μm, 
depending on the wavelength of illumination (473–632 nm).
The detection objective lens (25×, 1.0 NA CLARITY objective, Olympus) is inserted into 
the immersion chamber. To prevent leakage of the medium from the chamber, we sealed the 
gap between the chamber and the objective with an O-ring and a flexible latex film, in which 
only the tip of the detection objective is immersed. This setting allows the objective to move 
uninterruptedly during data acquisition while maintaining a sealed connection. The 
immersion chamber is created with a 3D printer (ABS plastic) and it is filled with glycerol to 
prevent evaporation-induced aberrations in RIMS medium.
Adjacent to the detection objective, we use tube lenses with different focal lengths to change 
the magnification of the light-sheet microscope and, consequently, its field of view. Higher 
magnification is used to digitally sample the acquired images in line with the high NA of the 
detection lens. We typically use magnification values between 25× and 55×, with the 
corresponding field of view of 0.28–0.06 mm2. To acquire the images, a camera with a light-
sheet mode feature is used (Zyla 4.2 sCMOS, Andor), in which the scanning light sheet and 
the camera pixel readout are synchronized to improve the signal-to-noise ratio121.
To rapidly scan large volumes, the sample is constantly translated using a xyz-theta stage, 
whereas the light sheet remains stationary. The xyz-theta stage is mounted on heavy-duty 
stainless steel bars to prevent sample vibration during data acquisition. To connect the 
sample holder to the xyz-theta stage, we first place the sample in a quartz cuvette filled with 
RIMS solution. The cuvette is then attached to a 3D printed cap that has a Luer lock female 
connector mounted on top, and laboratory Parafilm is used to seal the connector-cuvette 
interface. The sample holder is then attached to a xyz-theta stage via the Luer lock male 
connector.
To automatically scan large volumes using the microscope, we wrote a MATLAB program, 
which runs μManager75 and serial communication, both controlling and synchronizing the 
various mechanical components. This program finds the synchronization parameters to run 
the camera in a light-sheet mode, performs autofocus for the detection objective and 
optimizes the lateral position of the illumination light sheet. To this end, both the 
illumination lens and the detection objective are mounted on computer-controlled linear 
stages.
 Computer for visualization workflow—We perform visualization workflows for a 
sample single channel, 8-bit, 30-GB image on a 64-bit Windows 8 machine with Intel 
i7-3770 CPU and 16 GB of RAM.
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 PROCEDURE
 Tissue preparation for PACT and PARS ● TIMING 2 h–1 d
1| Prepare the perfusion and hydrogel monomer solutions, including 1× PBS 
containing 0.5% (wt/vol) NaNO2 (optional, for vasodilation) and 10 U/ml heparin 
(optional, for anticoagulation; hPBS), 4% PFA in 1× PBS and the A4P0 hydrogel 
solution.
▲ CRITICAL STEP 4% PFA should be freshly prepared. A4P0 may be freshly 
prepared or stored at −20 °C until use. For the latter, thaw A4P0 on ice before use. 
Perfusion solutions should be ice-cold. Discard PFA and hydrogel stock solutions if 
a precipitate is observed.
2| Anesthetize the animal with an intraperitoneal (i.p.) injection of Euthasol (100 
mg/kg of body mass for mice and rats), or according to institutional guidelines for 
rodent euthanasia (e.g., carbon dioxide inhalation until loss of consciousness, 
injection of pentobarbital or similar).
! CAUTION Follow appropriate institutional and governmental guidelines and 
regulations for husbandry, handling and euthanasia of laboratory animals.
3| Transcardially perfuse122 the subject with ice-cold hPBS until the perfusate drains 
clear from the right atrium (~20 ml at 10 ml/min for mice, ~100 ml at 50 ml/min 
for rats).
▲ CRITICAL STEP The perfusion pressure (flow rate) during transcardial 
perfusion and during PARS (unless otherwise noted) should approximate the 
physiological pressure of the subject's circulatory system; at night, mice and rats 
have systolic and diastolic pressures (mm Hg) of ~125/90 (mouse) and 121/84 (rat), 
respectively. When using a peristaltic pump123 or alternative pressurized system122, 
we suggest a rate of 10 ml/min for mice and ~100 ml/min for rats given that their 
cardiac output is reported to be ~10–35 ml/min (mouse124–126) and ~50–120 
ml/min (rat127), respectively, depending on sex, strain, age and so on124–127. If the 
perfusate is observed to leak out of the subject's nostrils, the cerebral vasculature 
was probably compromised by too high a flow rate; it is not advisable to proceed 
with PARS-based clearing of this subject, as PARS reagents may not reach all 
tissues; instead, organs of interest can be excised and cleared by PACT. Decrease 
the perfusion flow rate for all subsequent transcardial perfusions and PARS-based 
clearing steps. For the initial perfusion fixation (Steps 3–4), gravity alone may be 
used to draw hPBS and PFA through rodent vasculature.
? TROUBLESHOOTING
4| Without introducing air to the perfusion tubing, continue to perfuse the animal with 
ice-cold PFA (~50–70 ml at 10 ml/min for mice, ~100 ml at 50 ml/min for rats).
▲ CRITICAL STEP Although there are several alternative fixatives to 4% PFA, 
many of them carry consequences that are particularly detrimental to the hydrogel-
embedding process and/or subsequent imaging of thick cleared samples. 
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Mechanistically, formaldehyde augments the conjugation of tissue components to 
the acrylamide scaffold via its formation of methylene bridges between peptide 
amines and acrylamide, and thus fixatives that lack this cross-linking ability will 
result in limited tissue-hydrogel hybridization. Although glutaraldehyde, which is 
commonly used for EM sample preparation, can penetrate and cross-link tissue 
more efficiently than formaldehyde, it also generates high autofluorescence that is 
more difficult to counteract in thicker tissues via standard aldehyde blocking 
measures.
5| For PACT-based clearing of excised tissue samples, including bones (PACT-deCAL 
variation), prepare tissue as described in option A. For PARS-based whole-body or 
whole-organ clearing using continuous perfusion through intact vasculature, 
proceed to option B. PARS-CSF allows within-skull clearing through the use of an 
indwelling guide cannula, which was either previously inserted for neurobiological 
or pharmacological studies or positioned specifically for PARS-CSF clearing. For 
PARS-CSF whole-brain or whole-spinal cord clearing using continuous perfusion 
through an intracranial cannula, proceed to option C.
▲ CRITICAL STEP After perfusion fixation, all tissue samples that contain 
endogenous fluorophores must be protected from light. Minimize unnecessary light 
exposure during long incubations (>1 h) by, for example, wrapping the sample 
containers in aluminum foil.
(A) Tissue preparation for PACT
(i) Carefully excise whole organs and tissues to be processed with PACT.
(ii) If appropriate, slice whole organs into 0.5- to 3.0-mm-thick sections. 
Alternatively, pliable or fragile organs may be easier to thick-section, if 
required, immediately after hydrogel-embedding, which greatly increases 
their firmness, before proceeding to clearing (Step 7).
(iii) Postfix the samples in 4% PFA for 1–2 h at RT with gentle agitation on a 
rocking platform shaker.
■ PAUSE POINT The samples may be postfixed overnight at 4 °C. Fixing 
samples for longer periods of time, especially smaller, thinly sectioned 
tissues, may result in overfixation and antigen masking.
(B) Tissue preparation for PARS
(i) Set up the PARS chamber, tubing and pump. Prefill the PARS tubing with 
PFA so that no air bubbles are introduced into vasculature or-tissue. Fill the 
pipette box with PFA until it is about one-third to one-half full.
(ii) Transfer the perfused subject to the PARS chamber, laying the subject on top 
of the pipette wafer.
(iii) PARS reagents will be delivered through the same feeding needle catheter 
used during transcardial perfusion. Thus, after transferring the rodent to the 
PARS chamber, check the placement of the feeding needle catheter. The 
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catheter should enter the left ventricle. If it sits stably in the ventricle, leave 
it as is. Otherwise, advance the catheter through the left ventricle and into 
the aorta, just before the level of the aortic arch. Connect the PARS tubing to 
the feeding needle catheter.
▲ CRITICAL STEP Be careful not to tear rodent vasculature.
? TROUBLESHOOTING
(iv) Set the peristaltic pump to a flow rate of 1 ml/min and postfix the subject for 
1–2 h at RT. As 4% PFA is pumped through the feeding needle, PFA 
perfusate should exit the right atrium and drain into the pipette box. This 
perfusate is then drawn up through tubing and recirculated through the 
subject.
▲ CRITICAL STEP If necessary, add additional 4% PFA to the pipette box 
so that there is always enough PFA pooled in the pipette box to be 
recirculated through the tubing and subject vasculature. The amount of 
solution required for continuous recirculation will depend on the individual 
setup (size of the pipette box, liquid volume to fill tubing, evaporation from 
PARS chamber, species of subject and so on).
(v) To prevent PFA from cross-linking acrylamide within vasculature during 
subsequent steps, perfuse 1× PBS for 45 min at RT.
(C) Tissue preparation for PARS-CSF
(i) If an indwelling guide cannula is not available, insert an intracranial brain 
shunt (e.g., 20-G blunt needle) into the cisterna magna for spinal cord 
clearing, or lower the cannula through the skull (by drilling a hole in the area 
of interest and using tweezers to create an opening in the dura), to the level 
of the subarachnoid space, directly above the dorsal inferior colliculus18. 
Ensure that the cannula, whether newly inserted or existing, is firmly 
attached to the skull using dental acrylic (C&B-Metabond, Parkell), and that 
it is free from blockages.
(ii) Set up the PARS chamber, tubing and pump; prefill the PARS tubing with 
4% (wt/vol) acrylamide monomer solution (A4P0) so that no air bubbles are 
introduced into vasculature or tissue. Partially fill the pipette box with cold 
A4P0.
(iii) Transcardially perfuse with 4% PFA, and then briefly perfuse the subject 
with 1× PBS (≤30–60 ml for mice and rats, respectively) to wash away 
excess 4% PFA.
(iv) For whole-brain and whole-spinal cord clearing, ligate the arterial 
circulation, leaving the carotid arteries intact, and for rats or larger subjects 
remove tissue not directly perfused by these vessels to conserve reagents. 
Transfer the subject to the PARS chamber, positioning tissue atop the pipette 
tip wafer. For whole-brain clearing alone, if desired, decapitate the perfused 
subject and transfer only the head to the PARS chamber.
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(v) Connect the PARS tubing to the cannula.
 Formation of a tissue-hydrogel matrix ● TIMING 1 d
▲ CRITICAL The polymerization of tissue components with hydrogel monomers is 
crucial, as it ensures that SDS micelles preferentially solubilize and remove tissue lipids 
during clearing. We previously demonstrated that a minimal acrylamide-based network, 
which supports more rapid clearing, was nevertheless sufficient for stabilizing proteins and 
nucleic acid18. To increase the level of cross-linking without the addition of bis-acrylamide 
or PFA to the hydrogel monomer solution, the hydrogel-infused tissue should be carried 
through a rigorous degassing step.
6| Infuse the sample with A4P0 via passive diffusion for PACT-based clearing (option 
A), or via continuous perfusion of A4P0 and then thermoinitiator for PARS and 
PARS-CSF (option B).
(A) Hydrogel-embedding of PACT samples
(i) Transfer the PFA-fixed samples into a Vacutainer or conical tube with a 
rubber stopper. Fill the container with ice-cold A4P0 hydrogel solution until 
the samples are fully submerged. Incubate the samples at 4 °C overnight.
▲ CRITICAL STEP Once it is placed in monomer solution, the sample 
must remain at 2–8 °C. Warmer temperatures may cause premature 
polymerization of hydrogel monomers before they have uniformly diffused 
throughout the tissue sample.
? TROUBLESHOOTING
■ PAUSE POINT Samples may be incubated in A4P0 at 4 °C for 3 d.
(ii) Purge the samples and sample container of residual oxygen. Insert one 4-
inch-long hypodermic needle into the stopper so that the needle reaches near 
the bottom of the container, fully submerged in the hydrogel solution. Insert 
a second 1-inch-long needle into the stopper—this needle should not touch 
the hydrogel solution; its sole purpose is to vent excess gas from the 
container to avoid pressure buildup.
(iii) Connect the hypodermic needle to the nitrogen gas source (Fig. 2b) and 
slowly turn on the flow of nitrogen. Allow the nitrogen gas to bubble through 
the hydrogel monomer solution for 1–10 min before turning off the flow of 
nitrogen, and then remove both needles.
▲ CRITICAL STEP To form a more rigid tissue-hydrogel matrix, which 
imparts superior tissue cross-linking and only minor slowing of clearing and 
immunostaining steps, perform a more rigorous gas-exchange step. Place the 
sample container on ice and insert a 1-inch-long needle into the stopper. 
Connect the 1-inch-long needle to the house vacuum line and degas the 
sample for 5–10 min, depending on the sample size and volume of hydrogel. 
Gently tap or briefly vortex the sample container every minute to dislodge 
air bubbles from the tissue. Unhook the needle from the vacuum line, leaving 
Treweek et al. Page 29
Nat Protoc. Author manuscript; available in PMC 2016 June 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the needle inserted in the stopper so that it may serve as a venting needle 
during nitrogen exchange. Remove the sample-container from ice, insert a 4-
inch-long hypodermic needle that is connected to the nitrogen line into the 
stopper and bubble nitrogen gas into the hydrogel monomer solution for 5–
10 min. Turn off the flow of nitrogen. For larger tissue samples, such as 
whole rat organs, repeat the degassing process (degassing the sample on ice, 
and then bubbling nitrogen through the hydrogel solution). When this step is 
completed, remove both needles and proceed to Step 6A(iv).
(iv) Place the sample container in a 37 °C water bath for 2–3 h.
▲ CRITICAL STEP With rigorous degassing, the A4P0 solution will form 
a hydrogel having the consistency of honey or tacky silicone sealant, which 
is difficult to remove from the tissue. With a 1-min nitrogen gas exchange, 
the A4P0 solution will form a hydrogel with the consistency of syrup, which 
may be poured off easily.
(v) Remove the excess hydrogel from the tissue sample. Exercise caution when 
you are removing tacky hydrogel from the tissue: cut away excess hydrogel 
with a scalpel or small surgical scissors and then use a Kimwipe to carefully 
remove excess hydrogel from the tissue. Briefly rinse the samples in 1× PBS 
to wash away residual, syrupy-like, hydrogel from minimally degassed 
samples.
! CAUTION Hydrogel waste disposal should be conducted according to 
federal, state and local regulations.
(vi) Hydrogel-embedded samples will have increased rigidity and structural 
integrity, and indeed this may be the primary goal for some users. In this 
case, it is possible to transfer hydrogel-embedded soft tissues (e.g., pancreas, 
spleen, thymus) and amorphous biological samples (e.g., sputum, mucus, 
organoid cell masses) that were prepared in Steps 1–6 to other lines of 
experimental evaluation without proceeding with the PACT clearing 
protocol. All other users should proceed directly to Step 7 for instructions on 
how to chemically clear PACT samples.
? TROUBLESHOOTING
(B) Hydrogel-embedding of PARS samples
(i) Circulate 4% (wt/vol) acrylamide (A4P0) in 1× PBS through PARS tubing at 
RT overnight. Ensure that there is enough A4P0 pooled in the pipette tip box 
such that the tubing will not run dry during continuous recirculation.
(ii) Briefly perfuse the sample with 1× PBS to remove A4P0 and any residual 
PFA from the vasculature.
▲ CRITICAL STEP Use only enough 1× PBS to flush the vasculature of 
A4P0 (e.g., <5 ml for a mouse; 10 ml for a rat); do not infuse 1× PBS for so 
long that it displaces the A4P0 from tissue.
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(iii) Without disconnecting the perfusion lines, place the PARS chamber into a 
Ziploc bag and place the bag under nitrogen atmosphere (i.e., fill the bag 
with nitrogen gas, deflate the bag, refill it with nitrogen gas, seal the bag 
closed around the perfusion and set it aside for a few minutes while 
performing Step 6B(iv)).
(iv) Prepare 200 ml of 0.25% (wt/vol, final concentration) VA-044 initiator in 1× 
PBS; degas this solution via bubbling nitrogen gas through the solution for 
~10 min. Add this solution to the pipette box within the Ziploc bag, and 
place the bag-encased pipette box into a 37–42 °C water bath. If necessary, 
place a lead weight on top of the perfusion chamber to prevent it from 
tipping over. Turn on the pump so that the initiator circulates through the 
sample and PARS tubing, and allow the sample to incubate for 2–3 h in the 
water bath, replacing the solution with freshly `nitrogen-degassed' solution 
every hour. Alternatively, if the setup permits, the nitrogen gas can be 
bubbled directly into the 200 ml of 0.25% VA-044 initiator in 1× PBS that is 
already loaded into the pipette box while slowly degassing the chamber, as 
shown in Figure 7i. This requires disassembly of the PARS chamber to make 
an airtight environment with the Ziploc bag.
 Tissue delipidation with SDS ● TIMING 12 h–3 weeks
▲ CRITICAL The rate of tissue clearing depends on several parameters, including the 
inherent structural and biochemical properties of the tissue sample, the volume of the tissue 
sample, the hydrogel pore size and the density of tissue-hydrogel cross-linking, as well as 
the clearing setup (SDS concentration, incubation temperature and pH of clearing buffer). It 
is important for users to determine the clearing parameters for their specific tissue samples 
empirically, using these guidelines as a starting point for further optimization. Similarly, 
because the rate of clearing may vary greatly, tissues embedded in minimal hydrogel 
monomer compositions, such as the A4P0 hydrogel suggested here, are more susceptible to 
deteriorating when samples are left unattended in SDS.
7| Clear the tissue samples at 37–42 °C using either gentle agitation (PACT, option A; 
or PACT-deCAL, option B) or perfusion (PARS, option C); the latter accelerates 
micelle diffusion for rapid whole-body clearing. Although 8% (wt/vol) SDS is 
sufficient to solubilize lipids in soft tissue, 10% (wt/vol) SDS and EDTA are 
required to clear and decalcify bone (PACT-deCAL, option B). The PACT clearing 
procedure (option A) may be paused for 1–2 d by transferring the sample to PBS or 
diluted SDS (37–42 °C water bath, or at RT), and then returning the sample to SDS 
to resume clearing. Although a primary benefit of PARS clearing (option C) is its 
efficiency, if it is necessary to delay the PARS procedure, whole organs of rodents 
may be cleared via PARS and then stored for up to 1 month in PBS or in diluted 
SDS. However, if it becomes necessary to abort PARS (option C) because of 
unforeseen technical difficulties (examples of such issues that we have encountered 
include antibodies being out of stock at the manufacturer, an out-of-order 
microscope, compromised vasculature or leaky pump lines and a damaged PARS 
pump head), partially cleared samples can be excised and transferred into diluted 
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SDS for up to a month for storage or 8–10% (wt/vol) SDS to finish clearing via 
PACT (Step 7A(i)) or PACT-deCAL (Step 7B(i)). For delays within any of the 
methods of preparation (PACT, PACT-deCAL and PARS), it can be better for tissue 
quality to maintain excised cleared tissues in diluted SDS rather than storing 
samples after clearing/immunostaining in PBS or mountant. The latter case risks 
hydrogel disintegration, sample contamination and/or fluorescence signal loss.
? TROUBLESHOOTING
(A) PACT clearing
(i) Place each tissue-hydrogel sample into a 50-ml conical tube containing 
clearing buffer; gently rock the sample in a 37–42 °C shaking water bath 
until the tissue is optically transparent.
(ii) If you are using thin organ slices (<1 mm) embedded in A4P0, check the 
clearing progress every hour, as they should clear in <12 h. Similarly, porous 
tissue and samples with a high surface area–to-volume ratio may clear in less 
than 24 h. It is recommended that new users monitor the increasing 
transparency of such samples every 1–2 h during initial test runs. Once a 
sample's time to clear is determined empirically by the user, stringent 
monitoring is no longer necessary. Dense, highly myelinated or thick-
sectioned (1–4 mm) tissue and whole organs should be checked daily during 
clearing, and it may require >96 h.
▲ CRITICAL STEP Avoid overclearing. For certain organs, and for brain 
tissue in particular, variations in cell density and myelination cause specific 
regions to clear at different rates. Thus, some regions will become 
transparent, whereas the slower clearing regions will be only 
semitranslucent. Continuing to clear samples until all regions are uniformly 
transparent may lead to hydrogel softening, protein solubilization and/or 
structural deformity in the rapidly clearing areas. In addition, overclearing is 
deleterious to endogenous fluorescence. As tissue mounting in RIMS will 
lend an additional degree of optical transparency to tissues, it is crucial to 
remove tissues from SDS when the majority of tissue, or the portion of 
interest, is transparent, even if some regions appear undercleared. This will 
help ensure that the tissue macromolecular content is preserved. 
Alternatively, as opposed to terminating the incubation of tissue in 8% (wt/
vol) SDS prematurely, one may lower the percentage of SDS (e.g., from 8% 
to 4% (wt/vol) SDS) in clearing buffer at the final stages of clearing.
? TROUBLESHOOTING
(iii) Once the appropriate region of tissue appears optically transparent, wash the 
tissue extensively at RT with gentle shaking. For rapid tissue processing, 
conduct a minimal wash step of 4–5 buffer exchanges in 1× PBS over a 12- 
to 24-h period. Herein, residual SDS may precipitate, causing tissue 
cloudiness. To achieve more thorough removal of SDS, or to wash larger 
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tissue blocks, wash the samples in either BBT or PBST for 1–2 d, with 4–5 
buffer exchanges over the course of washing.
▲ CRITICAL STEP It is almost always preferable to perform wash steps 
of cleared samples at RT. We have found that additional 37 °C incubations of 
cleared tissue or, in particular, alternating between RT and 37 °C incubations 
are hazardous to tissue structural integrity, as cleared tissue lacks the 
structural support previously offered by lipids and thus must be handled with 
care. However, a single 37 °C sample wash after clearing and/or a final 
37 °C sample wash that precedes sample mounting (Step 10) may be 
beneficial to accelerating the diffusion of residual SDS from tissue and/or 
removing SDS precipitate, respectively.
■ PAUSE POINT Cleared and washed samples can be stored in 1× PBS (or 
PBST) containing 0.01% (wt/vol) sodium azide at RT for 1–2 d. Tissues may 
become cloudy from salt precipitate, in which case wash them with a few 
changes of PB.
(B) PACT-deCAL
▲ CRITICAL The following steps have been optimized for clearing the dissected 
tibia of an adult mouse. For other bone types, it is important to adjust the 
parameters of PACT-deCAL, such as the duration of bone incubations in clearing 
and decalcifying buffers, and the concentration of EDTA. Temperature fluctuations 
(e.g., from performing SDS or EDTA buffer changes with RT solutions rather than 
with prewarmed 37 °C solutions, or from a water bath that is unable to maintain a 
constant 37 °C environment) may adversely affect bone tissue morphology128.
(i) Place each bone-hydrogel sample into a 50-ml conical tube containing 10% 
SDS-PBS (pH 8.0) clearing buffer; gently rock the sample in a 37 °C 
shaking water bath for 2 d.
(ii) Transfer the sample into 0.1 M EDTA in 1× PBS, pH 8.0, and incubate it for 
≥2 d in the 37 °C shaking water bath.
▲ CRITICAL STEP Bone becomes soft and flexible when decalcified. 
Larger samples may require up to 6 d and up to 0.5 M EDTA to decalcify.
(iii) Replace the EDTA-PBS with fresh 10% SDS-PBS (pH 8.0), and continue to 
clear the sample in a 37 °C shaking water bath for 2 d.
(iv) Wash the sample in an excess volume of 1× PBS (pH 7.4) for 24 h, by 
performing three or four buffer exchanges.
? TROUBLESHOOTING
■ PAUSE POINT Cleared and washed samples may be stored in 1× PBS 
containing 0.01% (wt/vol) sodium azide at RT for 1–2 d.
(C) PARS clearing
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(i) After polymerization, wash the perfusion lines with 1× PBS, and then 
replace the wash buffer with 8% SDS-PBS (pH 7.5) clearing buffer. This 
procedure can be accomplished easily by removing the PARS chamber from 
the shaking water bath (optional), by turning off the pump, by removing 
excess initiator buffer from the PARS chamber and by replacing it with 100 
ml of 1× PBS to perform the wash. Circulate the wash buffer through the 
sample for 10 min. Afterward, replace the buffer with 8% SDS-PBS (pH 
7.5). Place the chamber back into the Ziploc bag and into the 37–42 °C water 
bath. Allow the SDS clearing buffer to recirculate through the system for 24 
h. Perform a buffer exchange with fresh 8% SDS-PBS (pH 7.5), by clearing 
the buffer daily until the recirculated fluid is no longer yellowish, after which 
the SDS solution can be refreshed less frequently (every 48–72 h).
■ PAUSE POINT Whole organs are rapidly cleared in situ using PARS. 
However, if the user requires a time delay between clearing and 
immunostaining steps or must discontinue the PARS procedure, hydrogel-
perfused whole organs may be excised after hydrogel polymerization (Step 
6B) or after the initiation of PARS clearing (Step 7C(i)), and then stored in 
4–8% (wt/vol) SDS at 37 °C for up to 1 month. This allows whole organs to 
clear slowly during storage; their clearing progress must be monitored, albeit 
infrequently (e.g., weekly), as smaller, porous organs may become 
completely transparent in <1 month, wherein they should be transferred into 
1× PBS (or PBST or BBT) containing 0.01% (wt/vol) sodium azide at RT. 
Ensure that all storage solutions contain 0.01% (wt/vol) sodium azide, and 
when you are ready to resume processing tissue follow the protocol steps for 
PACT-based clearing and labeling (Step 7A). Although this PACT-based 
clearing of PARS-prepared whole organs conserves reagents and minimizes 
the constant oversight required during PARS clearing, it negates the principal 
benefits of PARS: efficiency and uniform sample preparation.
? TROUBLESHOOTING
(ii) Check on the clearing progress daily. Add additional SDS buffer to the 
PARS chamber if necessary, as depending on how well the Ziploc bag is 
sealed around the perfusion tubing, some buffer may evaporate over time.
(iii) The sample can be continuously perfused for up to 2 weeks until all desired 
organs have cleared, even if some organs appear clear within the first 24–48 
h. Alternatively, if all but one or two organs appear sufficiently transparent 
after a few days, one may proceed directly to Step 7C(iv) to flush SDS from 
tissue, and then excise all organs. The one or two semiopaque excised organs 
are transferred into 8% (wt/vol) SDS to finish clearing via PACT (see Step 
7A), whereas the organs that cleared more rapidly are immediately promoted 
to passive immunostaining (optional) and mounting (Step 10) without further 
delay.
▲ CRITICAL STEP As with PACT clearing, it is possible to overclear 
PARS samples, wherein protein and other tissue components are solubilized 
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and the stabilizing hydrogel matrix begins to disintegrate. Generally, most of 
the major organs are cleared within a similar timeline of 24–48 h, whereas 
the whole brain can take 1–2 weeks.
(iv) Once the tissue appears optically transparent, perfuse eight buffer changes of 
200 ml of BBT or 1× PBS with 0.01% (wt/vol) sodium azide (pH 7.4) over a 
2-d period in the 37–42 °C water bath.
? TROUBLESHOOTING
8| For samples that will be immunolabeled after clearing, the hydrogel matrix will be 
required to support the cleared tissue for several rounds of washing and multiday 
incubations with gentle shaking. If the already delicate tissue-hydrogel matrix 
seems precariously fragile after clearing (this usually only occurs with thin-
sectioned tissue), it is advisable to repeat the hydrogel embedding and 
polymerization steps (Step 5A). This will stabilize tissue architecture during 
immunolabeling, prevent tissue loss or disintegration and counteract expansion in 
mounting medium. For cleared samples that will not undergo any 
immunohistochemical labeling steps before imaging, skip Steps 8 and 9, and 
proceed directly to Step 10.
 Single-cell phenotyping of cleared tissues ● TIMING 12 h–2 weeks
▲ CRITICAL PACT and PARS prepared tissues are amenable to most standard 
immunohistochemical protocols; a list of validated small-molecule dyes, primary antibodies 
and secondary fluorescent labels is provided in Table 4.
▲ CRITICAL This PARS-histology protocol is sufficient to label molecular targets in the 
peripheral organs of mice and rats, with antibody amounts adjusted for body size. Individual 
users may need to adjust the incubation times and/or lengthen wash steps.
9| Prepare the primary antibody cocktail in IHC buffer. An antibody dilution of 
1:200–400 is recommended; however, a more or less concentrated antibody dilution 
may be required, depending on the tissue identity and bimolecular target. Perform 
passive labeling (option A) or perfusion-assisted labeling (option B). For passive 
labeling schemes (option A), thick-sectioned tissues should be incubated in enough 
of the antibody cocktail to fully bathe all surfaces, usually a few milliliters of 
antibody cocktail or less, if the tissue is placed in a minimally sized container. For 
example, 1.5- to 5-ml Eppendorf tubes are recommended. For perfusion-assisted 
labeling using the PARS setup (option B), ~20–100 ml of primary antibody cocktail 
or labeling solution is required, depending on the tissue volume to be perfused and 
the total volume of the perfusion system (PARS tubing volume plus an additional 
amount of solution to partially fill the perfusion chamber).
? TROUBLESHOOTING
(A) Passive histology
(i) Incubate the tissues in the primary antibody cocktail at RT with shaking for 
3–7 d. For small-molecule stains or fluorescent dyes, a 1- to 3-d incubation 
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is usually sufficient, and thin tissue sections (<0.5 mm) may be stained 
within a few hours.
▲ CRITICAL STEP The duration of primary antibody incubation must be 
determined on a case-specific basis (see antibody penetration guidelines, Fig. 
4d). It is highly recommended to use smaller antibody formats for thick-
tissue staining, when available129. For A4P0-embedded rodent brain tissue, a 
full IgG will penetrate ~500 μm over a 3-d incubation at RT with shaking. 
This length of time is often sufficient for 1 mm tissue slices if the tissue can 
be imaged from either side. For A4P4-embedded rodent brain tissue, a full 
IgG will penetrate ~200 μm over a 3-d incubation at RT with shaking.
? TROUBLESHOOTING
(ii) To remove unbound antibody or stain, wash the samples in an excess volume 
of 1× PBS buffer: transfer the samples to a larger container (e.g., a 15- to 50-
ml conical tube) and perform four or five 1× PBS buffer exchanges over the 
course of 1 d. Larger tissue blocks, PACT-cleared whole organs, and samples 
in which high background or nonspecific antibody binding are common 
should be washed for 2 d in PBST, with four or five buffer exchanges.
? TROUBLESHOOTING
(iii) Prepare the secondary antibody cocktail (1:200–400 recommended dilution) 
in IHC buffer. Fab fragment secondary antibodies are preferred.
(iv) Incubate the washed samples in the secondary antibody cocktail for 2–5 d at 
RT and with shaking. Again, samples may be transferred to 1.5- to 5-ml 
Eppendorf tubes in order to accomplish staining with a minimal volume of 
antibody.
(v) Wash labeled samples with four or five buffer exchanges of 1× PBS over 1 d.
? TROUBLESHOOTING
(B) Perfusion-assisted labeling
(i) Replace the PBST in the perfusion tubing and PARS chamber with the 
primary antibody cocktail or stain and continuously perfuse the sample for 3 
d.
(ii) Exchange the antibody cocktail for 1× PBS, and wash the sample by 
perfusing four buffer changes of 200 ml of 1× PBS over the course of 1 d.
(iii) Prepare the secondary antibody cocktail (1:200–400 recommended dilution) 
in IHC buffer. Again, Fab secondary antibodies are preferred.
(iv) Replace the 1× PBS in the perfusion tubing and PARS chamber with the 
secondary antibody cocktail (or stain), and continuously perfuse the sample 
for 3 d.
(v) Exchange the antibody cocktail for 1× PBS, and wash the sample by 
perfusing four buffer changes of 200 ml of 1× PBS over the course of 1 d.
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? TROUBLESHOOTING
 RIMS for PACT and PARS samples ● TIMING 1 d
10| Calculate the RI of the tissue to be mounted and imaged. Use a refractometer to 
measure the sample RI according to the manufacturer's instructions.
11| Prepare a sample-optimized RIMS formulation by adjusting the amount of 
Histodenz dissolved in 0.02 M phosphate buffer (for common RI recipes see Fig. 
6b, Supplementary Fig. 1b). For most tissues, a RIMS formulation with RI ~1.46–
1.47 is optimal. For bone, prepare a graded series of RIMS formulations: RIMS 
with RI ~1.42, RIMS with RI ~1.46 and RIMS with RI ~1.48–1.49. For imaging 
thick tissue using immersion objectives corrected for immersion medium with an 
RI between 1.38 and 1.42, it is sometimes beneficial to match the RI of the RIMS 
to that of the immersion medium. For example, when using the LD-Plan 
Apochromat 20× 1.0 NA Scale objective (Zeiss), RIMS with RI ~1.42 will help 
reduce image distortion in the z-direction.
▲ CRITICAL STEP As discussed in the Experimental design section, different 
mounting solutions can be substituted for RIMS.
12| Submerge the sample in excess RIMS (i.e., in a capped 15- or 50-ml conical tube, 
or in a 5-ml Eppendorf tube, filled three-fourths full with RIMS) and incubate it at 
RT until it reaches the desired transparency. Although thin tissue sections may 
become transparent in less than a single day, a whole rat brain requires a 1-week 
incubation in RIMS to achieve thorough RI homogenization throughout the sample. 
These incubation times may be shortened substantially by placing samples on a 
nutating mixer. Bone should be carried through a graded series of RIMS 
formulations, each with a progressively higher RI. For example, incubate cleared 
bone in RIMS-1.42, then in RIMS-1.46, and lastly in RIMS-1.48-1.49 for 1 day 
each before mounting. Similarly, perform a graded series of RIMS incubations for 
very fragile tissues, as this will prevent the unlikely event of tissue damage from 
rapid shrinking and swelling.
▲ CRITICAL STEP Upon RIMS immersion, cleared tissue will shrink over the 
course of a few hours (e.g., A4P0-embedded coronal mouse brain sections shrink 
~20%, size fluctuations are reduced in samples embedded in PFA-containing 
hydrogels). Continued incubation in RIMS will lead to gradual tissue expansion 
back to its starting size as RIMS penetrates the tissue. These size changes may 
confound the visualization of (sub)cellular morphology or introduce apparent tissue 
deformities. Thus, imaging should not be undertaken before the sample has 
equilibrated in RIMS. However, if the goal is coarse cellular phenotyping and/or 
rapid tissue visualization, a much shorter RIMS incubation may be performed (1–4 
h, or until the sample is sufficiently transparent).
? TROUBLESHOOTING
■ PAUSE POINT Samples may be stored for the long term (~3 months) in RIMS. 
Herein, RIMS-submerged samples should be kept in an airtight container at RT and 
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protected from light. Alternatively, when short-term sample storage at 4 °C is 
mandatory, samples may be mounted in cRIMS; store it in a dry, airtight container.
13| Transfer the RI-homogenized tissue into an airtight container (e.g., Vacutainers or 
conical tubes with rubber stoppers) and fill the container with fresh RIMS (or with 
an alternative mounting medium such as sRIMS or 87% (vol/vol) glycerol) until it 
just covers the sample. Insert a 1-inch-long needle into the rubber stopper, connect 
the needle to the house vacuum line, and degas the sample for 5–10 min. When you 
are ready to image, proceed to the next step for mounting instructions.
▲ CRITICAL STEP Although RIMS outperforms sRIMS in our hands, the 
primary ingredient of sRIMS—sorbitol—not only offers a cost advantage over 
Histodenz but also is commonly available in research laboratories, owing to its 
broad use as a cell culture reagent. Importantly, sRIMS grants superior imaging 
resolution over glycerol.
▲ CRITICAL STEP For fine-scale analysis (e.g., of subcellular morphology) or 
lengthy image acquisition, do not image samples immediately after their placement 
in RIMS. Wait until their initial expansion after RIMS-mounting has plateaued 
(e.g., several days after mounting 1-mm slices).
▲ CRITICAL STEP It is crucial that RIMS or other mounting media be prepared 
with 0.01% (wt/vol) sodium azide to prevent microbial growth in mounted tissue. 
Limit the number of air bubbles in sealed slides.
? TROUBLESHOOTING
 Acquisition ● TIMING 1 h to several days
14| Mount and image tissues with a confocal microscope (option A) or with a light-
sheet fluorescence microscope (option B).
(A) Confocal imaging
(i) Prepare glass slides with appropriately sized tissue wells, such as 0.5- to 1.0-
mm thick iSpacers, which may be stacked to create deeper wells, or silicone 
sheets, which may be cut to size. If the silicone spacer is adhesive free, apply 
vacuum grease to the edge of the spacer. Place samples inside the spacer. 
Slightly overfill the spacer with RIMS and place a coverslip on top of the 
spacer. Gently press down to seal the coverslip. Remove overflow RIMS 
with a Kimwipe.
(ii) Place RI-homogenized, thick-sectioned tissues and small whole organs on a 
glass slide: place the tissue inside the sample well; overfill the well with 
fresh, degassed RIMS of an appropriate RI such that it forms a convex 
meniscus. Take care not to introduce bubbles into RIMS, or between the 
tissue and slide.
(iii) Place a cover glass over the sample well, using vacuum grease or nail polish 
to seal the cover glass onto the well edges. Again, avoid sealing bubbles into 
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the sample well; if this occurs, remove the cover glass and repeat this step, 
adding more RIMS to the well as necessary.
(iv) To image PACT- and PARS-cleared samples with a standard microscopy 
setup (e.g., a single-photon confocal microscope), use a multi-immersion 
objective with a RI correction collar to match the RI of the mounted sample: 
RI ~1.46–1.47 for most tissues, or ~1.48–1.49 for bone. For immersion 
medium, use glycerol with the same RI as the mounting RIMS.
(v) Determine optimum acquisition parameters, and apply these. Acquisition 
parameters (e.g., photomultiplier tube (PMT) gain, laser power and scanning 
speed) need to be optimized for each sample on the basis of-the desired final 
image quality.
▲ CRITICAL STEP To allow for accurate stitching, acquisition software 
should be set to acquire tiles with overlap (>10%). If the microscope has the 
option, it is useful to use the auto Z brightness correction (Fig. 4b). In Zen 
(Zeiss), Auto Z provides an automatic gradual adjustment of the detector 
gain, amplifier offset, amplifier gain and laser intensity setting between the 
first and last optical slice of a z-stack. This will help ensure that signal 
intensity is uniform throughout the sample, as even clear tissue will scatter at 
depth.
(B) Light-sheet microscopy
(i) Mix the glycerol in the immersion chamber using a pipette tip (Fig. 9) to 
prevent optical aberrations because of inhomogeneous medium, and let the 
glycerol settle for ~1 h.
(ii) Stabilize the sample in a quartz cuvette by submerging the sample in RIMS 
within the cuvette and by arranging gel pieces around the sample. We use 
1% (wt/vol) low-melt agarose gel.
(iii) Position the cuvette on the custom sample holder, which may be 3D printed 
(Supplementary Data 2), and attach it to the sample translation stage, as in 
Figure 9b.
▲ CRITICAL STEP Make sure that the cuvette is properly sealed (e.g., 
with Parafilm; see Fig. 9b), as evaporation of water from RIMS will cause 
severe aberrations.
(iv) Before lowering the sample in the immersion chamber, verify that the light 
sheet is centered in the field of view and that the objective lens is in focus.
(v) Lower the sample into the immersion chamber.
(vi) Re-adjust the light-sheet position to the center of the field of view and re-
focus the objective lens.
(vii)Change the settings of the camera to a light-sheet mode, activate the driving 
voltage of the galvo scanner via the function generator and trigger the 
camera using the external trigger. The delay between the galvo scanner and 
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the camera's external trigger signal should be fine-tuned in order to achieve 
optimal synchronization; here we used a custom MATLAB program to 
automatically find the optimum delay; the software is available upon 
demand.
(viii)Set the image acquisition parameters (e.g., laser power, scan depth and the 
scan resolution in z) and initiate the acquisition sequence.
 3D image visualization ● TIMING 1 h
▲ CRITICAL We outline workflows for tracing and visualization using tools summarized 
in Table 3. Interactive processing and visualization software will perform best on a 
workstation with substantial RAM (>16 GB) and GPU memory (≥1 GB). The tools 
mentioned are multi-threaded, and they can often exploit multicore processors to further 
speed up computations.
15| For the volumetric visualization of large images that do not fit in RAM, select one 
of the following workflows: (option A) using Imaris (Bitplane); (option B) using 
TeraStitcher and Vaa3D TeraFly; or (option C) using Vaa3D TeraConvert plug-in 
and Vaa3D TeraFly. Estimated timing is based on tests with a 30-GB image stack 
visualized on a 64-bit Windows 8 machine with Intel i7-3770 CPU and 16 GB of 
RAM.
(A) Imaris (v7.7.1)
(i) Stitch image tiles using the acquisition software.
(ii) Open the raw image stack (~12 min).
(iii) Save the loaded images in Imaris .ims format (~24 min). This is useful to 
streamline future loading and visualization. Reloading the resulting .ims file 
thereafter takes a few seconds.
(iv) Visualize the images using the Imaris volumetric view `Surpass', and then 
annotate and perform additional image processing using Imaris XTensions.
(B) TeraStitcher and the Vaa3D TeraFly plug-in (v2.921/v0.999)
▲ CRITICAL STEP Stitch the tiles and save a multiresolution volume using 
TeraStitcher (Step 15B(i–iii), also see ref. 62); visualize the resulting image using 
the Vaa3D TeraFly plug-in in Step 15B(iv–v).
(i) Store individual fields of view as separate .tif stacks in a hierarchical set of 
subdirectories as used by TeraStitcher using the layout specified in https://
github.com/abria/TeraStitcher/wiki/User′s-guide.
(ii) Stitch images using either the TeraStitcher standalone program or the Vaa3D 
plug-in (`Plug-In→Image_stitching→TeraStitcher→Tera stitcher'). 
TeraStitcher requires that the user specify the voxel dimensions, tile size and 
tile overlap used during acquisition.
(iii) Save the stitched output as a tiled, multiresolution volume.
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(iv) In Vaa3D, start the TeraFly plug-in (`Plug-In→TeramanagerTera→Fly') and 
select the directory containing the exported `multi-res tiled volume'.
(v) The 3D view window will now display the whole image data set and 
progressively load in higher-resolution subvolumes as the user zooms in to 
particular parts of the image. Use Vaa3D's color map, annotation and 
analysis tools on selected subvolumes.
(C) Vaa3D TeraConvert and TeraFly plug-in (v2.921/v0.999)
▲ CRITICAL STEP Use the Vaa3D TeraConvert plug-in to convert an already 
stitched image to tiled, multi-res format (Step 15C(i–ii)), and then use the Vaa3D 
TeraFly plug-in to visualize the resulting image by following Step 15C(iii–iv).
(i) Stitch images using the acquisition software. Save individual z-sections as a 
numbered sequence of files in a single directory using either acquisition 
software export options or by using the `BioFormats importer' plug-in in Fiji 
to load as a `Virtual Stack' and then using the `BioFormats exporter' plug-in 
to save as an OME-TIFF file130,131 (http://www.openmicroscopy.org/site/
support/ome-model/ome-tiff/), by selecting the option to save each channel 
and z-section in a separate file.
(ii) Use TeraConvert plug-in (`Plug-In→Teramanager→TeraConverter') to 
convert the stored images into a multiresolution `tiled volume' by specifying 
the location of the image series and specifying `Vaa3D raw tiled format' and 
an output directory.
▲ CRITICAL STEP Pay attention to `Estimated RAM usage' in the 
TeraConvert plug-in window. To reduce the memory needed by TeraConvert, 
deselect the checkboxes next to the lowest resolution output formats (starting 
from the one with the smallest x,y,z values) until the `estimated RAM' is less 
than the available RAM.
(iii) In Vaa3D, start the TeraFly plug-in (`Plug-In→Teramanager→TeraFly') and 
select the directory containing the exported multi-resolution `tiled volume'.
(iv) The 3D view window will now display the whole image data set and 
progressively load in higher-resolution subvolumes as the user zooms in to 
particular parts of the image. Use Vaa3D's color map and annotation and 
analysis tools on selected subvolumes.
 3D image analysis ● TIMING variable
▲ CRITICAL A typical workflow is to first run automated tracing to generate initial 
estimates of morphology and then to perform more detailed semiautomated editing to refine 
the tracing. Automated tracing is computationally intensive, so it is essential to restrict 
processing to small ROIs or cropped-out subvolumes and to manually merge the traces 
afterward. In addition, it is worth noting that semiautomated and manual editing of traces 
can be greatly accelerated by taking time to learn keyboard shortcuts for a given software 
tool rather than clicking on graphical user interface elements such as menus or buttons.
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16| Automate the tracing of relevant image elements using either neuTube (option A) 
or Imaris (option B). Alternatively, one may perform tracing using the Vaa3D-
Neuron2 plug-in, which has been reviewed previously62. The sample workflows in 
options A and B and the times reported here are based on our tracing of the test 
image (Supplementary Data 3) shown in Figure 10.
(A) neuTube (v1.0) ● TIMING 3 min
(i) Load the image into neuTube. For commercial image formats that are not 
recognized by neuTube, use the Fiji `BioFormats importer' and `BioFormats 
exporter' plug-ins to convert to .tif format.
(ii) Select `View→3D View' to visualize a volumetric rendering. Click the 
`Transfer Function' under the `Control and Settings' panel to adjust contrast 
in the 3D view (i in Fig. 10a and Supplementary Fig. 7a). In a large volume 
containing many cells, center the cursor on an ROI and right-click and select 
`Open Zoom In View' to show only image data for a subregion.
(iii) Left-click on a cell body and select `Trace' to automatically trace a neurite 
from that point. Successively visit the remaining untraced neurites associated 
with the cell, and click `Trace' on each (ii in Fig. 10a).
▲ CRITICAL STEP neuTube includes a fully automatic tracing option, but 
we found a semiautomatic tracing approach (which requires 1–2 clicks per 
neurite) to be faster and more reliable.
? TROUBLESHOOTING
(B) Imaris (v7.7.1) ● TIMING 10 min for whole test image, less for smaller ROIs
(i) Load the image file. Make sure that the voxel dimensions are correct via the 
`Edit→Image Properties…' menu, and correct them if necessary. Use 
`Display Adjustment' to adjust the contrast.
(ii) Add a new `Filament' to the `Surpass Scene' session.
(iii) In the AutoPath tracing wizard, select the `AutoPath' algorithm and select 
the ROI checkbox.
▲ CRITICAL STEP Specify the smallest possible ROI enclosing each 
neuron of interest to ensure fast processing (i in Fig. 10b and Supplementary 
Fig. 7b).
(iv) Adjust thresholds for automatic detection of starting points (i.e., soma) and 
seed points (ii in Fig. 10b). The goal is to have seed points distributed along 
the neurites, but avoid extra seed points in the background, which will slow 
tracing and produce errors that need to be corrected later. Depending on 
background noise and morphological complexity, it may be faster to identify 
starting and seed points by manual shift+clicking. The `Autopath wizard' 
will then find paths connecting seed points into a tree of neurite segments.
? TROUBLESHOOTING
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17| Within the same program (neuTube or Imaris, respectively), manually refine the 
automated tracing results that were that were generated in Step 16. Stepwise 
instructions are presented for both neuTube (option A) and Imaris (option B).
▲ CRITICAL STEP We believe that the following guidelines for manipulating 
automated results will be broadly applicable to a variety of tracing projects. 
However, they do not represent an exhaustive list of the capabilities of the software, 
and the user should not feel limited to this set of keystrokes.
(A) neuTube (v1.0) ● TIMING 10 min
(i) After initial tracing yields good coverage of neurites, select and delete 
erroneous nodes, add connections and extend fibers by selecting nodes and 
using the right-click context menu (iii and iv in Fig. 10a). See the extensive 
tutorial on editing at http://www.neutracing.com/manual/.
(ii) To save tracing results, use `File→Save SWC'. Alternately, `File→Export 
Scaled SWC' allows the user to specify the relative scaling of the x,y and z 
axes to match acquisition parameters and to produce SWC data in physical 
units.
? TROUBLESHOOTING
(B) Imaris (v7.7.1) ● TIMING 10 min
(i) Manually refine the automatically traced result from `AutoPath'. For 
example, users can extend individual traced paths by adding seed points and 
manually editing to correct errors.
(ii) If necessary, remove incorrect branches using `branch select mode' and the 
delete key. To split branches, use the `node select mode' and delete 
individual nodes. Select a pair of end points and the `Join' option to find a 
path between them (iii in Fig. 10b).
(iii) To extend neurites using the `AutoPath' method, select the `filament' 
corresponding to the traced component to be extended, and choose 
`Selection as Starting Point' to perform shortest path computation. Once the 
computation is done (~10 min for whole test image, less for smaller ROIs), 
the AutoPath mode will interactively trace from the cursor position back to 
the selected component. Shift+clicking will add the displayed candidate path 
(iv in Fig. 10b).
(iv) If necessary, use the filament editing tools to perform additional operations 
such as smoothing filaments, estimating neurite diameter, detection and 
annotation of spines, and fully manual tracing (refer to user manual for 
details).
(v) Visualize the resulting traces using Imaris Vantage or export tracing 
geometry in NEURON .hoc file format (see ref. 132, or for an up-to-date list 
of NEURON .hoc resources: http://www.neuron.yale.edu/neuron/
publications) for use in other analysis tools.
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? TROUBLESHOOTING
? TROUBLESHOOTING
Troubleshooting advice can be found in Table 5.
● TIMING
Steps 1–5, tissue preparation for PACT and PARS: 2 h–1 d
Step 6, formation of a tissue-hydrogel matrix: 1 d
Steps 7 and 8, tissue delipidation with SDS: passive, 10–240 h (PACT on thin- and thick-
sectioned tissue), 1 week (PACT-deCAL), or up to 1 month (whole-brain clearing via 
PACT); active: 1–4 d (PARS, all organs except brain) or 1–2 weeks (whole-brain clearing 
via PARS)
Step 9, single-cell phenotyping of cleared tissues: 12 h (labeling with small-molecule dyes) 
to 2 weeks (primary and secondary antibody labeling and nuclear staining with 24- to 48-h 
wash steps)
Steps 10–13, RIMS for PACT and PARS samples: 1 d
Step 14, acquisition: 1 h to several days (variable depending on tissue volume, the number of 
distinct color labels or channels, the desired resolution and the microscope setup)
Step 15, 3D image visualization: ~1 h
Steps 16 and 17, 3D image analysis: variable based on analysis goals
 ANTICIPATED RESULTS
PACT, PARS and RIMS collectively form a tissue clearing toolkit that is versatile, user-
friendly and sample-friendly across tissue types. Building on past research18, we detail here 
how both PACT and PARS methodologies are amenable to rapid, high-throughput 
histopathology of rodent (Fig. 1a–e) and human (Fig. 1f,g) tissue samples alike, whether 
through the visualization of natively expressed fluorescence markers (Figs. 1a–e, 5c and 9c; 
Supplementary Fig. 3d,e) or through immunolabeling whole-organ and thick tissue samples 
(Figs. 1f,g, 4b,c, 5d and 6a; Supplementary Fig. 6b) after clearing. Furthermore, the 
formation of a cross-linked, tissue-hydrogel matrix allows for rigorous detergent-based 
clearing with only minimal leaching of proteins into the clearing buffer (Fig. 3a and 
Supplementary Fig. 2a,b) and no detectable loss in YFP fluorescence between uncleared and 
cleared samples (see Yang et al.18). In addition to its RI-matching capability, RIMS also 
serves to preserve the molecular content of mounted samples: no protein was measured to 
leach out of mounted samples after a 1-week incubation, and YFP fluorescence was readily 
detected in cleared samples that were stored in RIMS for 3 months18. The enhanced optical 
transparency of delipidized and RI-matched tissues permits high-resolution detection of 
endogenously expressed fluorescent proteins, antibody-labeled proteins and nucleic acid 
transcripts at the single-molecule level (FISH18), usually with similar intensity to and lower 
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background signals than are seen in uncleared tissues (Fig. 5c,d, confocal images for control 
versus cleared samples; Supplementary Fig. 4).
Among the recently developed PACT variations summarized here are dedicated protocols for 
specialty cases within tissue clearing. These include PACT-processing of fragile tissue 
samples (Figs. 3–5), pre-PACT tissue staining with Sudan Black B to mask autofluorescence 
in thick tissues (Supplementary Fig. 3 and Supplementary Methods), PACT-deCAL for 
clearing and imaging fluorescently labeled bone (Fig. 6a) and ePACT for tissue clearing 
through expansion (Supplementary Fig. 4 and Supplementary Methods). With respect to the 
latter, PACT tissues have previously been carried through to FISH studies, in which clearing 
and slight tissue swelling benefitted the visualization of single, labeled transcripts18. In 
ePACT, cellular components that were once poorly resolved in uncleared sections become 
visible (Supplementary Fig. 4b). Combining these techniques offers the potential to optically 
distinguish multiple transcripts or otherwise packed multicolor labels (e.g., neuronal 
positioning system, NPS133) within the expanded sample space of a cell.
To accompany these methods for chemically clearing a variety of tissue types, we extended 
our RIMS formulation guidelines to include recipes for different tissue types (i.e., to better 
match the RIs of different samples; see Fig. 6b and Supplementary Fig. 1b). As PACT and 
PARS have now been optimized to clear a wide variety of tissues, the method can further 
benefit from exploring alternative labeling schemes for visualizing protein and nucleic acid 
targets in thick tissues (Supplementary Fig. 6). Although traditional antibody-based labeling 
methods have been used very effectively to illuminate cell phenotype and tissue morphology 
(Figs. 1g and 5d and previous work18), they can be both cumbersome and costly. The slow 
penetration of full-format immunoglobulins in thick tissue necessitates long incubations 
(Fig. 4b–d), to the detriment of sample integrity. Herein, camelid nanobodies 
(Supplementary Fig. 6) and protein affinity tags (i.e., SNAP-tag134, Halo-tag135, CLIP-
tag136, TMP-tag137, and Spy Tag Catcher138) present chemically stable and potentially cost-
effective alternatives. With the ability to easily penetrate thick tissue, these reagents can 
recognize and bind their respective targets, either a cognate antigen or tagged protein, with 
high specificity and rapid kinetics. In addition, by using dyes that are several-fold brighter, 
highly photostable and easier to separate spectrally than fluorescent proteins, protein affinity 
reagents can provide an excellent signal-to-noise ratio in labeled tissues139.
Two major bottlenecks in the translation of fixed, unprocessed tissue banks into analyzable 
image databases are (i) acquisition time of thick tissues at high resolution and (ii) the 
computational demands to convert raw image stacks into manageable data sets for 
phenotypical and morphological study. Light-sheet microscopy has recently been applied to 
imaging large cleared volumes as it substantially reduces the acquisition time15. Here we 
provide a basic scheme for relatively inexpensive design of a light-sheet microscope that 
enables fast and high-resolution imaging of cleared samples (Fig. 9a,b and Supplementary 
Table 1), and we show its compatibility with PACT. A representative volume (1 mm depth) 
PACT-cleared mouse brain slice imaged at 45 frames per second can be seen in Figure 9c. In 
comparison with traditional confocal microscopes, a frame rate of 45 frames per second 
shows ~10–100 times improvement in image acquisition speeds and thus allows for rapid 
imaging of large cleared samples, in addition to its recognized utility for live-cell 
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imaging140. In addition to increased speed, light-sheet microscopy substantially reduces 
photobleaching141, which is crucial for imaging dim samples and especially for conducting 
smFISH experiments, in which the 20–100 single fluorophore–labeled probes are used to 
visualize individual transcripts.
Regardless of the microscopy setup, image acquisitions for large tissue samples generate raw 
data files that are on the order of gigabytes or even terabytes in size. These data must be 
converted into a file format that allows data handling and visualization on computer 
workstations that are available to standard research laboratories. Many software packages for 
image analysis were not designed to accommodate such file sizes and inevitably crash 
partway through the computational process. Thus, we have endeavored to present a broadly 
applicable workflow for image data handling (Fig. 10 and Table 3), which will guide the 
user through the process of transferring raw image files into the image analysis software 
packages that we feel are most capable of performing basic functions such as tract-tracing 
and cell mapping.
In summary, we have validated the ability of PACT, PARS and RIMS to prepare a variety of 
tissue samples for imaging via confocal and light-sheet microscopy. With these methods in 
hand, biologists may tackle the broad spectrum of scientific demands, from the meticulous 
analysis of isolated cell niches to the global interrogation of intact biological systems.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Applications of whole-organ and whole-organism clearing protocols. (a–e) PARS-based 
whole-body clearing for assessing cellular-level adeno-associated virus (AAV) tropism 
(Supplementary Methods). Three weeks after systemic injection of AAV9:CAG-GFP, mice 
were PARS-cleared and their organs were excised and sectioned for imaging. (a,b) 
Projection images show GFP+ transduced cells in the adrenal gland. Arrow highlights a GFP
+ cell near the surface of the adrenal gland with neuronal morphology, which is shown in 
higher magnification in b. (c) Projection images show GFP+ cells in the stomach from the 
surface to the lumen. GFP expression is particularly high in the myenteric plexus. (d,e) 
AAV9 transduces cells in several layers within the intestine (duodenum). (d) Projection 
image of GFP fluorescence. Double colored lines correspond to the positions of 50-μm 
maximum projection images extracted from the data set and presented in e. (e) GFP+ cells in 
the intestinal crypt (top), submucosal plexus (middle) and myenteric plexus (bottom). (f,g) 
Islet distribution within human pancreatic tissue. (f) A 2-mm-thick section of an adult 
human pancreas (top) was rendered transparent (bottom) with the PACT method. Briefly, a 
2-mm-thick section was cut from a 4% PFA-fixed human pancreas, incubated in 0.5% PFA 
and 4% (wt/vol) acrylamide at 4 °C overnight and then polymerized in fresh A4P0 hydrogel 
monomer with 0.25% VA-044 thermal initiator for 2 h at 37 °C. The tissue was cleared with 
4% SDS-PBS (pH 7.5) for 48 h, immunostained and mounted in sRIMS (~50% (wt/vol) 
sorbitol in 0.02 M PB, RI of 1.44). (g) The islet distribution was visualized by 
immunostaining for insulin (red), somatostatin (green) and DAPI (cyan) (see Table 4 for 
details on antibodies and nuclear stain); panels represent an imaging stack of 70 μm. 
Magnified regions are designated by yellow and blue boxes. Sparsely distributed islets are 
easily located with only 5× magnification (left). A group of islets were identified at 10× 
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magnification (right, top), and a 3D image of a single islet was captured with a 25× 
magnification (right, bottom). All images were collected on a Zeiss LSM 780 confocal 
microscope with the Fluar 5× 0.25 NA M27 air objective (w.d. 12.5 mm), Plan-Apochromat 
10× 0.45 NA M27 air objective (w.d. 2.0 mm) and the LD LCI Plan-Apochromat 25× 0.8 
NA Imm Corr DIC M27 multi-immersion objective (w.d. 0.57 mm). Experiments on 
vertebrates conformed to all relevant governmental and institutional regulations, and they 
were approved by the Institutional Animal Care and Use Committee (IACUC) and by the 
Office of Laboratory Animal Resources at the California Institute of Technology.
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Figure 2. 
PACT setup and procedure. To successfully hybridize tissue with hydrogel monomers via 
free-radical polymerization, the sample and hydrogel solution must be incubated at 37 °C in 
an oxygen-depleted environment. This is best accomplished within an airtight container that 
permits sample degassing. (a) Supplies for PACT chamber (left): 50-ml conical tube (large 
sample) or Vacutainer (small sample), size 7 stoppers that fit the 50-ml conical tube, PTFE 
tubing, needles, syringes and a razor blade or scissors to cut the syringe in half. Construct a 
degassing line that will allow a sample tube to be evacuated of oxygen using the house 
vacuum and then be placed under inert nitrogen atmosphere (a, left to right). (b) The PACT 
procedure for sample degassing and hydrogel polymerization is as follows (b, top row): 
prepare the hydrogel monomer solution, taking care to keep all reagents ice-cold; infuse the 
tissue sample with hydrogel monomer solution at 4 °C; insert the vacuum line needle into 
the stopper and place the container under house vacuum for 5–10 min; remove the vacuum 
line and insert both a venting needle and the hypodermic needle, which is connected to the 
nitrogen gas line tubing; bubble nitrogen gas through the sample and solution for 5–10 min, 
ensuring that the venting needle allows excess pressure to escape from the PACT container; 
and quickly remove both needles and place the sample and container in a 37 °C water bath 
for 1–3 h. (b, bottom row) Once the hydrogel has polymerized, pour off excess hydrogel, 
rinse the sample with 1× PBS and/or tissue off with a Kimwipe, section the sample 
(optional) and place the sample into a 50-ml conical tube filled with 8% (wt/vol) SDS 
clearing buffer. Incubate the sample at 37 °C in a shaking water bath until the sample is 
clear. Thoroughly wash the cleared sample, immunostain (optional) and then incubate the 
sample in RIMS to improve its optical clarity.
Treweek et al. Page 58
Nat Protoc. Author manuscript; available in PMC 2016 June 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
PACT protein loss and tissue expansion for different hydrogel and clearing conditions. A 
detailed comparison of the protein loss and tissue expansion for eight different hydrogel 
matrix compositions: A4P0, A4P1, A4P2, A4P4, A4P0B0.05, A4P4B0.05, A2P0B0.025 and 
unhybridized, and four different clearing buffers: 8% SDS-PBS (pH 7.5), 8% SDS-PBS (pH 
8.5), 8% SDS-BB (pH 8.5) and 8% SDS in 0.1 M PB (pH 7.4). Perfused and fixed mouse 
brains were sliced into 1-mm-thick coronal slices, and combinations of all the different 
hydrogel and clearing conditions were performed on slices from comparable locations. 
Slices were monitored and imaged every 12 h, and the clearing buffer was collected for 
protein loss measurements and replaced. (a) Total protein content within each sample of 
clearing buffer collected throughout the clearing process was measured by the bicinchoninic 
acid assay by extrapolating the concentration of protein from a standard curve of BSA 
concentration in each clearing buffer (Supplementary Fig. 2a). Protein amounts from each 
time point were summed until each slice was completely clear, resulting in a measure for the 
total amount of protein lost while clearing for each slice. This total protein loss was then 
compared with the initial weight of each slice (n = 3). A comparison was also made with the 
protein loss of 100-μm-thick slices that were not cleared, but were permeabilized with PBST 
overnight (n = 9). (b) Comparison between total width and height tissue expansion between 
hydrogel compositions (n = 4). (c) Tissue expansion comparisons with different clearing 
conditions (n = 8). (a–c) Data are presented as mean ± s.e.m. Experiments on vertebrates 
conformed to all relevant governmental and institutional regulations, and they were approved 
by the Institutional Animal Care and Use Committee (IACUC) and by the Office of 
Laboratory Animal Resources at the California Institute of Technology.
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Figure 4. 
Clearing time course and antibody penetration of PACT-processed samples. Quantitative 
comparison of the effect of different hydrogel-embedding conditions and clearing buffers on 
time to clear and antibody penetration during immunostaining. 1-mm-thick mouse coronal 
slices were hybridized and cleared with the array of previously used PACT conditions (Fig. 
3). Slices were monitored for the time they took to become transparent. Once cleared, slices 
were washed and then immunostained. (a) Representative images of two 1-mm-thick 
coronal brain slices (~1.0–0.0 mm anterior to bregma142) through the time course for PACT 
clearing and a comparison of time to clear (mean ± s.e.m.) for each PACT hydrogel 
composition. For the representative images, slices were cleared with 8% SDS-PBS (pH 8.5) 
and incubated in RIMS for 24 h. (b) Imaging of antibody penetration through different 
PACT tissue preparations. Previously cleared and washed 1-mm-thick slices were 
immunostained for parvalbumin (red) and nuclei stained with DAPI (cyan), using 2-d 
incubations with the primary and Fab format secondary antibodies (for immunostaining 
reagents, see Table 4), transferred to RIMS for 5 h and then RIMS-mounted. Samples from 
the cortex, traversing the depth of the slice, were imaged on a Zeiss LSM 780 confocal 
microscope with a Plan-Apochromat 10× 0.45 NA M27 air objective (w.d. 2.0 mm). To 
ensure even illumination throughout the depth of the slice for fair antibody detection, we 
applied laser power z-correction (Zen software, Zeiss): power was changed linearly for each 
slice, shown as a gradient next to each image; starting power values at the top were chosen 
to match the level of fluorescence at the surface across slices, whereas the range of powers 
varied for different PACT conditions. Shown are images of staining through A4P0, A4P1 
and A4P4 hydrogel-embedded samples, as well as unhybridized tissue, cleared with 8% 
SDS-PBS (pH 7.5). As antibody and small-molecule dye diffused through both the top and 
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bottom surfaces of the slice simultaneously, the images show that within 2 d DAPI has fully 
penetrated in all of the conditions, whereas antibody labeling has progressed to varying 
extents, depending on the PACT condition. As slices cleared with the different conditions 
also swell to different extents during the process (indicated by their difference in height 
relative to the pre-clearing height of 1 mm, as indicated by the white dotted lines in b), 
penetration of antibody through a more swollen sample will either require longer diffusion 
time or faster diffusion rate to reach an equivalent anatomical depth as in a less swollen 
sample. Incomplete detection of the DAPI signal in A4P1 and A4P4 slices is due to the 
difficulty of achieving similar light penetration in highly cross-linked slices. (c) Depiction of 
parvalbumin staining through same slices as in b. DAPI signal has been removed to better 
show the variable penetration of the antibody over the course of a 2-d period. (d) 
Quantification of antibody penetration through PACT conditions depicted in b and c. 
Antibody fluorescence signal was scaled by the average DAPI intensity for each z-section 
inside the volume and the average scaled fluorescence along a line perpendicular to the 
tissue surface produced a final estimate of labeling intensity (in arbitrary units, a.u.) as a 
function of tissue depth (Supplementary Methods). Antibody diffusion was fit to an 
exponential model [f(x) = a × exp (−tau × x) + b], with the exponent tau being inversely 
proportional to the square root of the diffusivity, wherein a larger tau indicates slower 
diffusion. Labeling intensities for A4P0, A4P1, A4P4 and unhybridized samples cleared 
with 8% SDS-PBS (pH 7.5), as a representative sample of all the different buffers, are 
plotted on a logarithmic scale. The amount of PFA contained in the hydrogel-tissue matrix is 
inversely proportional to immunohistochemical staining efficiency. Experiments on 
vertebrates conformed to all relevant governmental and institutional regulations, and they 
were approved by the Institutional Animal Care and Use Committee (IACUC) and by the 
Office of Laboratory Animal Resources at the California Institute of Technology.
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Figure 5. 
Preservation of tissue architecture during delipidation. The differential effects of individual 
clearing conditions on cellular architecture and endogenous and stained fluorescence 
imaging. (a–c) Mice that received bilateral intracranial injections in the lateral septum of 
AAV expressing the tdTomato transgene were perfusion-fixed with 4% PFA, and a subset of 
1-mm-thick unhybridized coronal brain sections were prepared for microscopy without 
clearing (control, first column), or they were first rendered transparent via the CUBIC 
method11,21 (second column). The second subset of 1-mm-thick sections underwent PACT-
processing: A4P0 embedding (third column) or A4P4 embedding (fourth column) and 
clearing with 8% SDS-PBS (pH 7.5), followed by preparation for ultrastructural study or 
RIMS mounting. (a) Brain sections were photographed after fixation (control) or 
immediately after clearing (CUBIC, A4P0 and A4P4) to illustrate the degree of tissue 
swelling that occurred for each condition. (b) Control (unhybridized, uncleared), CUBIC-
cleared and PACT-cleared (A4P0, A4P4) tissues were then processed identically for 
ultrastructural examination using electron microscopy and tomography (Supplementary 
Methods). Overviews (top row) from each of the four samples illustrate the relative amount 
of lipid loss attributable to the different clearing methods, in terms of contrast between 
structures. Tomographic reconstruction (bottom row) of subregions of the overviews, each 
showing a portion of an axon and surrounding cellular structures, indicates the extent of 
change at the fine-structural level. (c) Control, PACT- and CUBIC-cleared brain sections 
were mounted in RIMS or CUBIC reagent-2 (refs. 11,21), respectively, and the endogenous 
expression of tdTomato was imaged on a Zeiss LSM 780 confocal microscope with the LD 
LCI Plan-Apochromat 25× 0.8 NA Imm Corr DIC M27 multi-immersion objective (w.d. 
0.57 mm). Volume renderings (top: x,y,z = 300 μm for PACT- and CUBIC-cleared samples 
and x,y,z = 300, 300, 140 μm for control) and maximum intensity projections (bottom: x,y,z 
= 100,100,50 μm) are shown. In all images except the uncleared control, cells are visualized 
throughout the volume imaged. In the control image, light is unable to penetrate through the 
sample to image at depth. (d) Preservation of myelin proteins. 200-μm-thick A4P0-PACT-
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cleared mouse brain sections and 50-μm-thick uncleared sections were immunostained for 
SMI-312 and for myelin basic protein (MBP), using Atto 488–conjugated and Atto 647N–
conjugated Fab format secondaries (see Table 4 for details). After a 2-h RIMS incubation, 
the transparent sections were mounted and imaged on a Zeiss LSM 780 confocal microscope 
with the Plan-Apochromat 10× 0.45 NA M27 air objective (w.d. 2.0 mm) and the LD LCI 
Plan-Apochromat 25× 0.8 NA Imm Corr DIC M27 multi-immersion objective (w.d. 0.57 
mm). The images correspond to a 50-μm-thick maximum intensity projection over the 
dentate gyrus; Top: A4P0-PACT cleared, Bottom: uncleared smaller panels are high-
magnification images of the boxed areas showing myelinated axons. Experiments on 
vertebrates conformed to all relevant governmental and institutional regulations, and they 
were approved by the Institutional Animal Care and Use Committee (IACUC) and by the 
Office of Laboratory Animal Resources at the California Institute of Technology.
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Figure 6. 
PACT-deCAL and optimized RIMS formulation for imaging decalcified bone samples. (a) 
After perfusion fixation with 4% PFA, the right and left tibia bones were dissected and 
postfixed in 4% PFA overnight. One tibia was reserved as the uncleared control (top left), 
whereas the other tibia bone was A4P0-embedded and cleared (top right) according to 
PACT-deCAL, as follows. The tibia bone was first cleared in 8% SDS-PBS (pH 8) for 24 h, 
and then it was transferred into 0.1 M EDTA for 2 d and finally cleared further in 8% SDS-
PBS (pH 8) for 2 d at 37 °C. The cleared bone was washed in 1× PBS three times over 1 d 
and incubated in PBS containing 1:200 DRAQ5 for 2 d at 37 °C. The stained bone was 
quickly rinsed in 1× PBS and incubated in 1.49 RIMS overnight at 37 °C. The bright-field 
image (top right) depicts the resulting bone transparency via the placement of a ruler (small 
red box) underneath the tibia, wherein the tibia's outline on top of the ruler can be seen in 
the magnified inset of the ruler (large red box). The cleared tibia was imaged in two regions 
(yellow and blue boxes) on a Zeiss LSM 780 confocal microscope with the LD LCI Plan-
Apochromat 25× 0.8 NA Imm Corr DIC M27 multi-immersion objective (w.d. 0.57 mm). 
(b) RIMS may be formulated with different concentrations of Histodenz in order to achieve 
an RI that aligns with the tissue density and light-scattering properties of the sample to be 
imaged, as well as to the optical properties of the imaging setup (objective lens with or 
without immersion medium). RIMS with an RI ~1.47 is well suited for most cleared soft 
tissues (blue tick mark), whereas cleared bones should be incubated in RIMS with RI ~1.48–
1.49 (green tick mark). Rodent husbandry and euthanasia conformed to all relevant 
governmental and institutional regulations; animal protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) and by the Office of Laboratory 
Animal Resources at the California Institute of Technology.
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Figure 7. 
Assembling and working with the PARS chamber. (a) A completed PARS chamber used for 
whole-body tissue clearing. (b) Individual parts to build a PARS chamber: (1) three 1/8 × 
1/8-inch barbed connectors, (2) two 3/32-inch barbed male Luers with locking nut, (3) a 
1,000 μl pipette tip box, (4) a 1-gallon Ziploc freezer bag, (5) a three-way stopcock with 
Luer lock, (6) a 3/32-inch barbed female Luer with full tread, (7) a roll of lab tape, (8) a 22-
G × 1-inch gavage needle, (9) a 1/8-inch barbed male slip Luer, (10) a female Luer tee with 
locks, (11) clay and (12) Tygon E-lab tubing. Ruler shown is 5 cm in length. (c) Three 1/8-
inch holes are drilled into the pipette tip box: two into the box front and one into its side, all 
~2 cm below the top rim of the box. The three 1/8 × 1/8-inch barbed connectors are placed 
into the drilled holes. To connect the outflow line (blue tape bands on outflow line tubing), a 
piece of Tygon tubing is connected from the bottom inside of the pipette box to the single 
1/8-inch barbed connector that was inserted through the box side. (d) To continue the 
outflow line, a second, longer piece of blue-taped tubing is attached to the outer fitting of 
this same barbed connector (on the outside of the pipette tip box side), and then the other 
end of this tubing is threaded through the peristaltic pump, pulled back over toward the 
pipette box and finally connected to a three-way stopcock with a 3/32-inch barbed male Luer 
with locking nut (rightmost blue-banded tubing in d). To form the inflow line, a short length 
of tubing (green tape band) is used to connect the three-way stopcock to the front right 1/8-
inch barbed connector of the pipette box. The solute flushing line and nitrogen bubbling line, 
which are subserved by the same tubing (white tape band), are formed by another short 
length of tubing that joins the third port of the stopcock to the front left 1/8-inch barbed 
connector. (e) The inflow line is continued inside the pipette box, with the tubing coiled 
several times around the base of the box so that the solute will be reheated before it passes 
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through the feeding gavage into the subject. The solute flushing line and nitrogen bubbling 
line is continued inside the pipette tip box and taped to the bottom of the chamber (not 
shown). (f) The tip of the coiled inflow line tubing is threaded up through the tip wafer (see 
bird's-eye view of threaded wafer in a) and connected to a 22-G ×1-inch gavage needle with 
a 1/8-inch barbed male slip Luer. The gavage needle is secured with a short loop of Tygon 
tubing (~90 mm) threaded through two holes of the wafer. (g) During the polymerization 
step, the chamber is placed into a 37 °C water bath and sealed in a Ziploc bag. The tubing is 
attached to the chamber with three 1/8 × 1/8-inch barbed connectors punctured through the 
Ziploc bag. The Tygon tubing is reconnected from the outside of the bag and surrounded 
with clay to make an airtight seal. (h) The animal is placed onto the pipette tip box, and the 
22-G × 1-inch gavage needle is used to catheterize the heart. (i) The chamber is placed into a 
37 °C water bath. A female Luer tee, which is taped onto the lid of the pipette tip box, is 
punctured through the Ziploc bag, and this joint is sealed with clay to ensure an airtight seal. 
Finally, to accelerate polymerization, a vacuum line is connected to the female Luer tee to 
remove oxygen (orange arrow), and a nitrogen gas line (white arrow) is connected to the 1/8-
inch barbed connector to deliver a steady flow of nitrogen into the bagged system. The 
solute is continually circulated through the animal from the outflow line (blue arrow, which 
also indicates the direction of flow through blue-taped tubing) and inflow line (green arrow, 
which also indicates the direction of flow through green-taped tubing).
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Figure 8. 
Whole-body clearing of mice with PARS. (a) A4P0-hybridized organs shown before the 
start of clearing (left) and after 5 d of clearing with 8% SDS-PBS (pH 8.5) and overnight 
washing with 1× PBS at pH 7.5 (right). Numbers correspond to the extracted organs in b. (b) 
Extracted organs from the cleared mouse in a, pictured before (top) and after (bottom) RIMS 
incubation for 3 d. Black pointers correspond to the adrenal gland on the kidney and to the 
ovaries on the fallopian tubes. Each square represents 0.5 cm2. Rodent husbandry and 
euthanasia conformed to all relevant governmental and institutional regulations; animal 
protocols were approved by the Institutional Animal Care and Use Committee (IACUC) and 
by the Office of Laboratory Animal Resources at the California Institute of Technology.
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Figure 9. 
Light-sheet microscopy enables fast and high-resolution imaging of cleared samples. (a) A 
schematic diagram of the light-sheet microscope; M, mirror; DM, dichroic mirror; S, 
sample; EF, emission filter. The scientific CMOS camera (Zyla 4.2 sCMOS, Andor) is 
running in a light-sheet mode, in which the readout direction of the camera is unidirectional 
and synchronized with the scanning direction and speed of the light source. In this 
configuration, only the pixels that are illuminated will be recorded, thus improving the signal 
to noise ratio of the image. For ease of synchronization, the function generator, the camera 
and the oscilloscope are controlled using a custom MATLAB program. (b) An image of the 
3D-printed immersion chamber (see design in Supplementary Data 1), in which the 
CLARITY objective (Olympus 25× 1.0 NA multi-immersion objective, w.d. 8.0 mm) is 
immersed in glycerol, whereas the sample is within a quartz cuvette filled with RIMS. (c) A 
volume rendering (Imaris, Bitplane) and cross-sections at different depths of a cleared Thy1-
YFP mouse brain section (1 mm thick), taken with the light-sheet microscope. The intensity 
of the layers was normalized as per Imaris image processing function, i.e., the mean and s.d. 
of each layer were equalized to the mean and s.d. of the entire stack using linear 
transformation. The images were acquired at 45 frames per second (voxel size: 0.117 μm × 
0.117 μm × 0.25 μm, bit depth: 12). The cross-sections at different depths, which are 
perpendicular to the scan direction, are maximum intensity projections (Imaris) across a 5-
μm volume. A parts list for this setup is available in Supplementary Table 1.
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Figure 10. 
Two different workflows for cell tracing in neuTube and Imaris. (a) Tracing using 
neuTube67. (b) Tracing using Imaris 7.1 (Bitplane). Results shown here took 25 min for a 
novice user with ~5 h of total experience using each tracing tool. Total tracing time to 
achieve similar results was generally comparable, but we found neuTube to be more efficient 
for quickly tracing isolated neurites. (a) neuTube 3D visualization (i), neuTube 
semiautomated tracing result (ii), tracing error (iii), and manual correction (iv). (b) Imaris 
ROI selection (i), Imaris `Autopath' seeding (ii), manual correction of tracing error (iii), and 
trace extension using `Autopath' (iv). The original test mage on which semiautomated 
tracing was performed is provided in Supplementary Data 3.
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TABLE 1
Current and potential biomedicaL applications of PARS and PACT.
Application Cleared tissue Additional references
Biodistribution of chemicals or biologicals (e.g., virus 
infectivity, antibody and gene therapies)
Whole-body clearing (Fig. 1a–e) 143 – 150
Mapping discrete cellular niches, such as 3D genetic makeup 
and architecture of tumors, stem cell niches; potential for larger 
volume array tomography151,152
PACT of tumor biopsies18 and whole-body PARS 
for rodent cancer models
98,101, 153–157
Monitoring the progression of cell death and tissue damage 
(i.e., in stroke, peripheral infarcts), and the corresponding 
neurogenesis
PARS for whole-body, targeted vasculature 
fixation and immunolabeling
158,159
Tract tracing complex long-range fiber bundles (e.g., vagus 
nerve) and whole-body vasculature (i.e., both circulatory and 
lymphatic systems); short- and long-range cellular 3D 
mapping160 (including via neuronal positioning system (NPS)133, 
via Brainbow161 and via array tomography151,152)
PARS with whole-body targeted IHC, PARS-
CSF (spinal cord), PACT-deCAL for vertebral 
column, ePACT for subcellular spectral 
resolution of overlapping NPS vesicles, 
Brainbow labeling and FISH probes
39–41,133, 162–164
Following neurodevelopment (neural stem cell differentiation), 
neurogenesis and nerve/axon regeneration
PARS 14,165–169
Tracking myelination trajectory over lifetime and 
demyelination in disease states (autism, traumatic brain injury, 
multiple sclerosis)
PACT and PARS with IHC for myelin-associated 
proteins and markers of inflammation (Fig. 5d) 165
,170–173
Studying the brain-gut connection, microbiome, blood-brain 
barrier permeability
PARS 174,175
Assessing the effects of peripheral immunoactivation on 
cognition and health
PARS with IHC for cytokines, inflammation and 
neuronal markers
171,172,176
Imaging through dense, complex tissues (e.g., bone marrow 
stem cells)
PACT-deCAL for through-bone labeling and 
imaging
97,164, 177–182
Exploring topics in microbiology, including biofilms 
(characterizing biofilm structure and the interaction of different 
cellular layers), the heterogeneity and distribution of microbes 
that occupy the same niche
PACT with considerations for fragile samples 
(e.g., PACT-hydrogel formulated with 
paraformaldehyde and/or bis-acrylamide) so that 
bacterial colonies are retained in tissue or biofilm 
samples during clearing
183 – 186
Diffusion tensor imaging (DTI)187 and spectral confocal 
reflectance microscopy (SCoRe, for label-free in vivo imaging 
of myelinated axons)188
Future potential for ex vivo variation of DTI, 
wherein PARS-based diffusion of materials and 
immunolabels grants whole-organism imaging
166,188–191
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TABLE 3
Image analysis and visualization tools.
Name Platform Stitching Out-of-core visualization Semiautomated tracing Notes
Imaris (Bitplane) Commercial Win/Mac No Yes Yes
Filament Tracer plug-in
Best loading 
and volumetric 
rendering of 
large (out-of-
core) images
Vaa3D62,63,66 Open Source Win/Mac/Linux Yes
iStitch70 or 
TeraStitcher69 
plug-in
Yes
TeraFly plug-in66
Yes
Vaa3D-Neuron2 plug-in66
Fiji60,61 Open Source Win/Mac/Linux Yes
Stitching plug-in71
Partial
Virtual Stacks, Data 
Browser plug-ina, or 
BigDataViewerb (ref. 80)
Yes
Simple Neurite tracer64,81
neuTube67 Open Source Win/Mac/Linux No No Yes Fastest 
semiautomated 
tracing 
interface
A list of image analysis tools appropriate for processing data from cleared tissue volumes including functionality for stitching, visualization and 
tracing. This list is far from exhaustive (consult refs. 87,88 for a broad survey), but it includes those that we tested and found most effective on our 
data sets.
a
Data Browser ImageJ plug-in (LOCI), see http://loci.wisc.edu/software/data-browser.
b
BigDataViewer, see http://fiji.sc/BigDataViewer.
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TABLE 4
Antibodies and small-molecule stains validated for cell-phenotyping in PACT- and PARS-processed tissues.
Label Supplier and/or formulation
Nucleic acid and molecular labels, cell-type and tissue-type small-molecule stains
DAPI Life Technologies (no. D-1306); 0.1–10 μg/ml
Hoechst Cell Signaling
NeuroTrace 530/615 Red Fluorescent Nissl Stain Life Technologies (no. N-21482); 1:50 dilution
SYTO 24 Life Technologies (no. S-7559); 1:200 dilution
DRAQ5 Cell Signaling (no. 4084); 1:200 dilution
Acridine Orange Life Technologies (no. A-1301); 100 μg/ml dilution
Lectin, DyLight 488 conjugate Vector Laboratories (no. L-1174); 1:100 dilution
Methylene blue Sigma-Aldrich (no. 66720); 1 μg/ml
Atto-565-conjugated phalloidin Sigma-Aldrich (no. 94072); 1:100 dilution
Alexa Fluor 647–phalloidin Life Technologies (no. A-22287); 0.5 μM in PBS
Primary antibodiesa
Mouse anti-pan-cytokeratin (AE1/AE3) antibody, Alexa Fluor 488–
conjugated
EBiosciences (no. 53–9003); 1:100 dilution
Synthetic anti-GFAP nanobody, Atto 488–conjugated GFAP nanobody producing according to published methods194,195 1:100 
dilution (Purified GFAP nanobodies were first conjugated to Atto 488, 
Sigma-Aldrich, diluted in dH2O to 1 mg/ml stock and then diluted 
1:100 for tissue labeling)
Chicken anti-tyrosine hydroxylase (TH) IgY Aves Labs (no. TYH); 1:400 dilution
Chicken anti-glial fibrillary acidic protein (GFAP) IgY Aves Labs (no. GFAP); 1:400 dilution
Rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1) IgG Biocare Medical (no. CP 290A); 1:200 dilution
Rabbit anti–integrin-β4 and anti-integrin β5 IgGs Santa Cruz Biotechnology (β4: sc-9090, β5: sc-14010); 1:200 dilution
Rabbit anti–β-tubulin IgG Santa Cruz Biotechnology (no. sc-9104); 1:200 dilution
Rabbit anti-parvalbumin antibody Abcam (ab11427); 1:200–1:400 dilution
Mouse anti–β-spectrin II antibody BD Biosciences (612563); 1:200 dilution
Rabbit anti–α-adducin antibody Abcam (ab51130); 1:200 dilution
Goat anti–myelin basic protein antibody Santa Cruz Biotechnology (C-16: sc-13914); 1:200 dilution
Mouse anti–pan-axonal neurofilament SMI-312 antibody BioLegend (SMI-312); 1:500 dilution
Guinea pig anti-insulin antibody DAKO (A0564); 1:500 dilution
Goat anti-somatostatin antibody Santa Cruz Biotechnology (sc7819); 1:500 dilution
Secondary antibodiesb
Donkey anti-chicken IgY, available as Cy2c, Cy3d, Cy5e, Alexa 
Fluor 594f, Alexa Fluor 647g conjugates
Jackson ImmunoResearch (703-###-155), where ### = fluorophore 
code; 1:200 dilution
Donkey anti-goat IgG, available as Cy2c, Cy3d, Cy5e, Alexa Fluor 
594f, Alexa Fluor 647g conjugates
Jackson ImmunoResearch (703-###-155), where ### = fluorophore 
code; 1:200 dilution
Donkey anti-guinea pig IgG, available as Cy2c, Cy3d, Cy5e, Alexa 
Fluor 594f, Alexa Fluor 647g conjugates
Jackson ImmunoResearch (703-###-155), where ### = fluorophore 
code; 1:200 dilution
Donkey anti-mouse IgG, available as Cy2c, Cy3d, Cy5e, Alexa 
Fluor 594f, Alexa Fluor 647g conjugates
Jackson ImmunoResearch (703-###-155), where ### = fluorophore 
code; 1:200 dilution
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Label Supplier and/or formulation
Donkey anti-rabbit IgG, available as Cy2c, Cy3d, Cy5e, Alexa Fluor 
594f, Alexa Fluor 647g conjugates
Jackson ImmunoResearch (703-###-155), where ### = fluorophore 
code; 1:200 dilution
Reagentsh for FISH labeling18
20-mer oligo probes toward β-actin 1 nM each of 24 Alexa Fluor 594–labeled 20-mer oligo probes toward 
β-actin prepared in hybridization buffer
Slowfade Gold + DAPI Life Technologies (no. S-36938); mounting medium for smFISH 
samples
aAtto fluorescent dyes that possess an NHS ester moiety (available from Sigma-Aldrich) may be conjugated to the primary antibody; this 
eliminates the need to perform a secondary antibody incubation when imaging tissues via fluorescence microscopy.
bCyanine dyes are traditionally better able to withstand dehydration and embedding in nonpolar, plastic media, whereas DyLight and Alexa Fluor 
dyes are perceived as brighter than Cyanine dyes in aqueous medium. Both seem to work well in labeling thick, cleared tissue samples.
cCy2 code: 225.
dCy3 code: 165.
eCy5 code: 175.
fAlexa Fluor 594: 585.
gAlexa Fluor 647N: 605.
hSee Supplementary Methods for protocol.
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TABLE 5
Troubleshooting PACT and PARS protocols.
Step Problem Potential reason Solution
3, 5 (transcardial 
perfusion)
Incomplete exsanguination, or 
the absence of tissue 
stiffening with PFA perfusion
Catheter is not stably placed in the 
heart in order to deliver solutions into 
rodent vasculature; vasculature was 
compromised during initial hPBS 
flush because perfusion rate was too 
high; an insufficient amount of hPBS 
was pushed through vasculature such 
that blood remains in smaller vessels
Use a single suture (loop the thread around the 
aorta) or clip to secure the feeding needle in 
place at the level of the aortic arch; start the 
initial perfusion of hPBS at a slower rate, and 
flush twice the volume of hPBS through
6 (hydrogel 
monomer (HM) 
embedding)
Tissue damage during 
clearing; tissue seems to be 
unnecessarily fragile
Inadequate infusion of HM solution 
throughout tissue
It may be necessary to leave large tissue 
samples such as whole rat organs in HM for 
>12 h so that the monomer may fully 
penetrate the tissue
Tissue is structurally fragile or 
delicate
Consider including PFA (1–4%) in HM 
formulation for subsequent sample 
preparations; extend the postfixation step
Poor HM polymerization after 
37 °C incubation
Inadequate degassing Repeat degassing step (10 min under vacuum, 
10 min of nitrogen bubbling) and 37 °C 
incubation
Bad reagents Use fresh PFA for fixation; prepare HM 
solutions immediately before use and store the 
thermoinitiator, acrylamide and bis-
acrylamide stock solutions at 4 °C
Embedded tissue or biological 
sample is too fragile for non-
clearing applications (e.g., 
thin sectioning and imaging)
Insufficient density of tissue cross-
linking
Increase the concentration of PFA (1–4%) 
and/or include bisacrylamide (0.05%) in the 
HM formulation
7 (tissue clearing) Clearing rate appears to slow 
down before the tissue is clear
Clearing may slow down as the 
clearing buffer acidifies
Buffer-exchange the clearing solution
Dense cross-linking If A4P1–4 was used, remove PFA from PACT 
hydrogel formulation in subsequent 
experiments; reduce the PFA postfixation 
incubation time by half
Tissue is dense, highly myelinated 
and/or otherwise difficult to clear
Continue incubating in clearing buffer while 
checking periodically. Consider PARS 
clearing rather than PACT clearing for 
peripheral organ samples, as perfusive force 
accelerates clearing rate
Tissue appears to degrade Bacterial contamination Buffer-exchange the clearing solution, adding 
0.01–0.05% (wt/vol) sodium azide to PBS-
based clearing solutions
Poor hybridization of tissue to HMs In subsequent clearing experiments, prepare 
the hydrogel monomer solution with fresh 
reagents, increase the PFA content by 1%, 
extend the tissue incubation in HM by 12–24 
h and/or before polymerizing the tissue-
hydrogel, perform two rounds of degassing 
(where one round equals 10 min under 
vacuum and 10 min nitrogen-bubbling)
Poor PFA cross-linking of tissues Ensure that adequate fixation and postfixation 
steps are performed; use fresh 4% PFA
Hydrogel softening during 
clearing
Overclearing and/or initial poor 
hydrogel polymerization
Consider doubling the postfixation step or 
including PFA in the HM formulation in 
subsequent experiments; consider 
underclearing tissue, as RIMS incubation will 
cause translucent tissues to become 
transparent for imaging
Difficulty obtaining complete 
bone decalcification
PACT-deCAL procedure requires 
further optimization by the user 
according to the bone size and 
Experiment with EGTA-based chelation and 
then 8% (wt/vol) SDS clearing. Alternate 
steps for `7B PACT-deCAL' are as follows:
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Step Problem Potential reason Solution
density (guidelines provided are 
specific to the mouse femur and 
tibia)
(i) Incubate bone-hydrogelin 0.1 M EGTA in 
1× PBS (pH 9) for 72 h at 37 °C.
(ii) Rinse the sample in 1× PBS; clear it in 8% 
SDS-PBS (pH 7.4) for 7 d at 37 °C, 
performing one buffer exchange during 
clearing.
(iii) Wash the sample as usual: 24–48 h in 3–6 
buffer changes of 1× PBS at RT
Dense, fibrous bone or larger 
samples may be resistant to 
decalcification by chelating reagents 
and SDS-based clearing alone
As bone consists of ~16% collagen196,197, 
consider incubating bone in collagenase 
before clearing in order to disrupt the collagen 
matrix
Tissue becomes turbid; white 
precipitate appears in the 
tissue
Incomplete washing after clearing, 
causing SDS and/or salts to 
precipitate in tissue when it is moved 
from 37 °C to RT
Double the time for of all wash steps, making 
sure to perform several exchanges of 1× PBS 
each day; wash with PBST or BBT instead of 
1× PBS
Tissue becomes white and nearly 
opaque upon transfer to 4 °C
Salts and, in particular, residual SDS will 
precipitate in tissue if it is moved to 4 °C. 
However, the precipitate should disappear 
upon gradual warming of tissue to RT or 
37 °C. Consider performing more extensive 
wash steps in future experiments, particularly 
after SDS clearing
Slight tissue yellowing during 
clearing
Use of PFA-containing hydrogels or 
BB
We have not observed adverse effects from 
slight tissue yellowing on imaging results—
tissue becomes clear upon RIMS mounting. 
However, very occasionally, some samples 
become very yellow during the first half of 
SDS clearing: these samples should be cleared 
for a longer length of time—until they are 
very transparent—or the yellowing will cause 
high background during imaging. Ensure that 
only fresh PFA is used in subsequent 
experiments
Brain does not become 
transparent during PARS-
based clearing
Insufficient perfusion with clearing 
buffer
Extend the clearing time: most rodent organs 
clear within 2 d via PARS; however, the brain 
requires an additional 1–2 weeks to clear. 
RIMS-mounting will also increase the 
transparency of `translucent' tissues
A specific organ does not 
clear well via whole-body 
PARS
Vasculature becomes compromised 
during the clearing process
Identify and try to fix leakages in the 
vasculature; if unsuccessful, tie off the major 
vessels supplying that organ, excise the organ 
for PACT clearing and continue to perform 
PARS clearing with the remaining body. 
Starting over with a new PARS preparation 
should only be used as the last resort
Poor flow to specific organ because 
of anatomic reasons (poorly 
vascularized)
If PACT is not a desirable option and the 
organ is sizable with accessible vasculature, 
consider PARS clearing the single organ, akin 
to published decellularization methods92
9 (histology) Poor labeling, including faint 
signal
Shallow antibody penetration Increase the antibody concentration in the 
primary antibody cocktail or replenish the 
antibody halfway through extended 
incubations, by either adding additional 
antibody directly to the original antibody 
cocktail or by preparing a fresh antibody 
dilution
Incomplete delipidation, which 
obstructs labeling
Increase the clearing time
High cross-linking density High cross-link density in A4P1-4–hybridized 
tissues will slow antibody diffusion; thus, 
antibody incubations should be extended
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Step Problem Potential reason Solution
Epitope loss or epitope masking 
(unlikely if adhering to protocol)
If tissue was damaged because of microbial 
contamination, consider adding 0.01–0.05% 
(wt/vol) sodium azide to all buffers and 
solutions that are used in long incubations; 
overfixation may lead to antigen masking, so 
postfixation steps should be decreased
In FISH experiments, degradation of 
nucleic acid transcripts, or diffusion 
of transcripts out of sample during 
clearing
Ensure that all hydrogel, clearing and labeling 
reagents are RNase-free; embed samples in a 
hydrogel formulation that contains PFA and/or 
bis-acrylamide (e.g., A4P1B0.05), and 
perform a rigorous degassing step to ensure 
thorough hydrogel-tissue hydridization
Poor quality of antibody or dye, 
which results in weak labeling
Only use high-quality antibodies that have 
been first verified in standard thin-section 
immunolabeling; experiment with a different 
antibody supplier—different antibodies 
against the same target may vary greatly in 
their labeling abilities, such as in their binding 
affinity and in their capacity to access 
intracellular compartments for cell-filling 
labeling versus only superficial or 
extracellular epitope binding. Finally, it can be 
helpful to simultaneously prepare a thin 
section (40–100 μm) alongside a thick, cleared 
section while troubleshooting to ensure that 
the visualization of a strong signal is possible
High background and/or 
autofluorescence
Tissue damage during processing Review procedures carefully, and ensure that 
no reagents introduced bacterial 
contamination of sample; lengthen the wash 
steps to remove potential precipitate (SDS, 
donkey serum–antibody immunocomplexes)
Sources of autofluorescence—part 1: 
fixative-induced autofluorescence, 
elastin, collagen
Many standard histological techniques for 
reducing autofluorescence, such as tissue 
bleaching23, performing wash steps in PBST 
containing 100 mM glycine to quench 
aldehydes and treating tissue with histology 
stains that quench or mask autofluorescence, 
may be adapted to thick-sectioned cleared 
tissues—typically by performing longer wash 
steps after the appropriate countermeasure; 
photobleaching the tissue before IHC at 
wavelengths that exhibit the highest 
autofluorescence may also help198
Sources of autofluorescence—part 2: 
heme chromophores, lipofuscins
Thoroughly remove all blood during initial 
cardiac perfusion; to elute heme, incubate 
hydrogel-embedded PACT sections and in 
particular PACT-deCAL sections in 
aminoalcohol (CUBIC reagent-1 (refs. 11,21) 
for 12–24 h at 37 °C with shaking, and then 
transfer the sections directly into 8% (wt/vol) 
SDS for clearing; lipofuscin autofluorescence 
is partially combatted by tissue clearing; 
however, thick tissue sections may be 
incubated in 0.2%199 to 1.0% ((wt/vol) final 
concentration) Sudan Black B for 1–3 hours 
immediately before Step 5 (PACT hydrogel-
embedding) in order to reduce high 
autofluorescent background—tissue clearing 
will allow Sudan Black B–treated sections to 
become sufficiently transparent for imaging 
(Supplementary Fig. 3)
High background, but with 
high signal of correctly 
labeled epitopes
Nonspecific antibody binding Extend the wash steps after both primary and 
secondary antibody incubations an additional 
day, by performing four or five buffer 
exchanges each day, and wash the samples in 
PBST instead of 1× PBS; in rodent tissue 
samples, avoid using antibodies that require 
anti-mouse secondary antibody labeling23; 
also some chicken antibodies show strong 
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Step Problem Potential reason Solution
staining with high background and/or 
aggregation—these antibodies should be 
diluted to 1:400 to 1:1,000
12, 13 (tissue 
mounting and 
imaging)
Poor image quality and/or 
poor imaging depth
Tissue is of insufficient transparency 
for light to penetrate
Extend the tissue incubation time in RIMS to 
several days before imaging; for bone, 
incubate for an additional 1 d in RIMS-1.48 or 
RIMS-1.49 before imaging
Morphological distortion Tissue size fluctuations Immediately before RIMS incubation, postfix 
cleared, immunolabeled tissue in 4% PFA for 
a few hours at RT, and then wash and incubate 
in RIMS for at least several days to one week 
before imaging; consider preparing future 
samples in hydrogel that contains PFA (e.g., 
A4P1–4, depending on the degree of swelling) 
and/or consider a longer postfixation step after 
transcardial perfusion
Bubbles in mounted tissue Air trapped in tissue or dissolved air 
in RIMS; sample mounted with 
insufficient RIMS, causing the 
introduction of air bubbles between 
the RIMS meniscus and cover glass
Purge RIMS of excess air via degassing the 
tissue in fresh RIMS before mounting (e.g., 
using the vacuum line, akin to the hydrogel 
polymerization of Step 5; do not bubble 
nitrogen through the sample following its 
placement under vacuum)—use this degassed 
RIMS to mount the degassed sample
Sample appears turbid or 
white
RIMS-mounted sample was placed at 
4 °C, causing salts, etc., to precipitate
The precipitate should disappear upon gradual 
warming of tissue to RT or 37 °C. Store 
RIMS-mounted tissue at RT, protected from 
light, or mount tissue in cRIMS for cold 
storage
16, 17 (3D image 
analysis)
Imaging software and/or 
computer crashes; unable to 
load acquired images
Insufficient RAM for large images Troubleshoot with a different option in the 
step 15 workflow: option A using Imaris, 
option B using TerraStitcher, or option C 
Vaa3D TerraFly; consider upgrading computer 
workstation and/or adding RAM and/or new 
graphics card; downsample the data set (note 
that compression cannot be used with Imaris); 
process the images in tiles (i.e., analyze each 
tile individually)
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